Chris Green Portrait

Chris Green

Conservative - Bolton West

Home Affairs Committee
26th Nov 2018 - 6th Nov 2019
Work and Pensions Committee
16th Oct 2017 - 20th Feb 2018
Science and Technology Committee
13th Jul 2015 - 3rd May 2017
Science and Technology Committee (Commons)
13th Jul 2015 - 3rd May 2017


Oral Question
Monday 6th December 2021
14:30
Department for Education
Oral Question No. 23
What recent discussions he has had with Cabinet colleagues on helping to ensure that communities are consulted on the location of new schools.
Save to Calendar
Division Votes
Wednesday 1st December 2021
Finance (No. 2) Bill
voted No - in line with the party majority
One of 296 Conservative No votes vs 1 Conservative Aye votes
Tally: Ayes - 215 Noes - 299
Speeches
Tuesday 30th November 2021
Oral Answers to Questions

T2. I welcomed the Government’s decision in 2019 to proscribe the Hezbollah terror group in its entirety, and I welcomed …

Written Answers
Thursday 25th November 2021
Genetics: Screening
To ask the Secretary of State for Health and Social Care, how much funding was allocated to the NHS Genomic …
Early Day Motions
None available
Bills
Thursday 8th March 2018
Forensic Science Regulator Bill 2017-19
The Bill failed to complete its passage through Parliament before the end of the session. This means the Bill will …
Tweets
Tuesday 30th November 2021
23:49
MP Financial Interests
Monday 26th July 2021
1. Employment and earnings
20 July 2021, payment of £275. Hours: 1 hr 18 mins. (Registered 22 July 2021)
EDM signed
Tuesday 23rd April 2019
Exiting the European Union
That an humble Address be presented to Her Majesty, praying that the European Union (Withdrawal) Act 2018 (Exit Day) (Amendment) …

Division Voting information

During the current Parliamentary Session, Chris Green has voted in 330 divisions, and 11 times against the majority of their Party.

22 Mar 2021 - Fire Safety Bill - View Vote Context
Chris Green voted No - against a party majority and against the House
One of 33 Conservative No votes vs 320 Conservative Aye votes
Tally: Ayes - 322 Noes - 253
10 Feb 2021 - Public Health - View Vote Context
Chris Green voted No - against a party majority and against the House
One of 24 Conservative No votes vs 327 Conservative Aye votes
Tally: Ayes - 526 Noes - 24
1 Dec 2020 - Public Health - View Vote Context
Chris Green voted No - against a party majority and against the House
One of 53 Conservative No votes vs 290 Conservative Aye votes
Tally: Ayes - 291 Noes - 78
4 Nov 2020 - Public Health - View Vote Context
Chris Green voted No - against a party majority and against the House
One of 33 Conservative No votes vs 308 Conservative Aye votes
Tally: Ayes - 516 Noes - 38
21 Oct 2020 - Additional Covid-19 Restrictions: Fair Economic Support - View Vote Context
Chris Green voted Aye - against a party majority and against the House
One of 2 Conservative Aye votes vs 339 Conservative No votes
Tally: Ayes - 261 Noes - 340
13 Oct 2020 - Public Health: Coronavirus Regulations - View Vote Context
Chris Green voted No - against a party majority and against the House
One of 42 Conservative No votes vs 298 Conservative Aye votes
Tally: Ayes - 299 Noes - 82
27 Apr 2021 - Fire Safety Bill - View Vote Context
Chris Green voted No - against a party majority and against the House
One of 31 Conservative No votes vs 320 Conservative Aye votes
Tally: Ayes - 320 Noes - 256
28 Apr 2021 - Fire Safety Bill - View Vote Context
Chris Green voted No - against a party majority and against the House
One of 32 Conservative No votes vs 321 Conservative Aye votes
Tally: Ayes - 322 Noes - 256
22 Nov 2021 - Health and Care Bill - View Vote Context
Chris Green voted No - against a party majority and against the House
One of 19 Conservative No votes vs 269 Conservative Aye votes
Tally: Ayes - 272 Noes - 246
30 Nov 2021 - Public Health - View Vote Context
Chris Green voted No - against a party majority and against the House
One of 19 Conservative No votes vs 268 Conservative Aye votes
Tally: Ayes - 434 Noes - 23
30 Nov 2021 - Public Health - View Vote Context
Chris Green voted No - against a party majority and against the House
One of 32 Conservative No votes vs 259 Conservative Aye votes
Tally: Ayes - 431 Noes - 36
View All Chris Green Division Votes

Debates during the 2019 Parliament

Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.

Sparring Partners
Nadhim Zahawi (Conservative)
Secretary of State for Education
(13 debate interactions)
Jacob Rees-Mogg (Conservative)
Lord President of the Council and Leader of the House of Commons
(10 debate interactions)
Maggie Throup (Conservative)
Parliamentary Under-Secretary (Department of Health and Social Care)
(7 debate interactions)
View All Sparring Partners
Department Debates
Department of Health and Social Care
(44 debate contributions)
Home Office
(23 debate contributions)
HM Treasury
(15 debate contributions)
View All Department Debates
View all Chris Green's debates

Bolton West Petitions

e-Petitions are administered by Parliament and allow members of the public to express support for a particular issue.

If an e-petition reaches 10,000 signatures the Government will issue a written response.

If an e-petition reaches 100,000 signatures the petition becomes eligible for a Parliamentary debate (usually Monday 4.30pm in Westminster Hall).

Petitions with highest Bolton West signature proportion
Petition Debates Contributed

We want the Government to commit to not rolling out any e-vaccination status/immunity passport to the British public. Such passports could be used to restrict the rights of people who have refused a Covid-19 vaccine, which would be unacceptable.

In the event of a spike we would like you not to close gyms as a measure to stop any spread of Covid. Also for gyms to not be put in the same group as pubs in terms of risk or importance. Gyms are following strict guidelines and most members are following rules in a sober manner.

Isolation essential to the Government’s strategy for fighting coronavirus, and UK citizens must remain healthy and exercise whilst keeping adequate distance between people. The Government should allow golf courses to open so families or individuals can play golf in order to exercise safely.


Latest EDMs signed by Chris Green

11th April 2019
Chris Green signed this EDM on Tuesday 23rd April 2019

Exiting the European Union

Tabled by: William Cash (Conservative - Stone)
That an humble Address be presented to Her Majesty, praying that the European Union (Withdrawal) Act 2018 (Exit Day) (Amendment) (No. 2) Regulations 2019 (S.I., 2019, No. 859), dated 11 April 2019, a copy of which was laid before this House on 11 April 2019, be annulled.
82 signatures
(Most recent: 29 Apr 2019)
Signatures by party:
Conservative: 73
Democratic Unionist Party: 7
Independent: 1
Non-affiliated: 1
View All Chris Green's signed Early Day Motions

Commons initiatives

These initiatives were driven by Chris Green, and are more likely to reflect personal policy preferences.

MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.


Chris Green has not been granted any Urgent Questions

Chris Green has not been granted any Adjournment Debates

2 Bills introduced by Chris Green


The Bill failed to complete its passage through Parliament before the end of the session. This means the Bill will make no further progress. A Bill to make provision for the appointment of the Forensic Science Regulator; to make provision about the Regulator and about the regulation of forensic science; and for connected purposes.


Last Event - 1st Reading: House Of Commons
Thursday 8th March 2018

A Bill to require those on the electoral register to produce proof of identity at polling stations before voting; and for connected purposes.


Last Event - 1st Reading: House Of Commons
Wednesday 23rd November 2016
(Read Debate)

Chris Green has not co-sponsored any Bills in the current parliamentary sitting


186 Written Questions in the current parliament

(View all written questions)
Written Questions can be tabled by MPs and Lords to request specific information information on the work, policy and activities of a Government Department
1 Other Department Questions
16th Sep 2020
To ask the Chancellor of the Duchy of Lancaster and Minister for the Cabinet Office, what the (a) average age and (b) median age is of people who have been reported of dying as a result of covid-19.

The information requested falls under the remit of the UK Statistics Authority. I have therefore asked the Authority to respond.

Chloe Smith
Minister of State (Department for Work and Pensions)
1st Oct 2020
What plans his Department has to introduce a national identity card.

The Government has no plans to introduce national identity cards.

Chloe Smith
Minister of State (Department for Work and Pensions)
17th Sep 2020
To ask the Chancellor of the Duchy of Lancaster and Minister for the Cabinet Office, how many people have died (a) with covid-19 symptoms and (b) from covid-19 to date.

The information requested falls under the remit of the UK Statistics Authority. I have therefore asked the Authority to respond.

Chloe Smith
Minister of State (Department for Work and Pensions)
20th Oct 2021
To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps his Department is planning to take to help ensure that changes to NICE methods and processes support the Life Sciences Vision's strategic goals.

The National Institute for Health and Care Excellence (NICE) plays a crucial role in sustaining the UK’s position as a life sciences superpower and will continue to play a pivotal role in delivering the ambitions set out in the Life Sciences Vision, which was co-developed by Government and the sector.

As reflected in Life Sciences Vision, NICE is continuing to deliver its high ambition Methods and Process Review. This will ensure NICE retains its global leadership in the evaluation and appraisal of new medicines and technologies.

The Department for Business, Energy and Industrial Strategy will continue to work closely with the wide range of public and private sector bodies and stakeholders across the sector, including NICE, to deliver the Life Sciences Vision.

George Freeman
Parliamentary Under-Secretary (Department for Business, Energy and Industrial Strategy)
20th Oct 2021
To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment his Department has made of the potential merits of the proposals for change to NICE methods and processes in the context of the Life Sciences Vision published in July 2021.

The National Institute for Health and Care Excellence (NICE) plays a crucial role in sustaining the UK’s position as a life sciences superpower and will continue to play a pivotal role in delivering the ambitions set out in the Life Sciences Vision, which was co-developed by Government and the sector.

NICE is continuing to deliver its Methods Review which will ensure NICE retains its global leadership in the evaluation and appraisal of new medicines and technologies. As an independent body, NICE is responsible for its own methods and processes.

The Department for Business, Energy and Industrial Strategy will continue to work closely with the wide range of public and private sector bodies and stakeholders across the sector, including NICE, to deliver the Life Sciences Vision.

George Freeman
Parliamentary Under-Secretary (Department for Business, Energy and Industrial Strategy)
8th Jun 2021
To ask the Secretary of State for Business, Energy and Industrial Strategy, what plans he has to encourage R&D investment in highly-skilled pharmaceutical manufacturing in the UK.

The UK Government will invest £14.9 billion in R&D this year, bringing investment to its highest level in four decades. This is a major step towards our commitment to increase total public and private R&D investment to 2.4 per cent of GDP by 2027.

Through the Manufacturing Made Smarter Challenge, the government will invest £147 million (matched by a minimum of £147 million from industry) to transform the UK’s manufacturing capabilities through the development and adoption of industrial digital technologies. The Challenge will support businesses to implement new tech to boost their manufacturing productivity, helping them reach new customers, create thousands of new highly skilled jobs, slash carbon emissions and reduce prices for customers.

The Government has also recently launched the Medicines and Diagnostics Manufacturing Transformation Fund (MDMTF), a £20 million fund offering capital grants to businesses, incentivising them to place internationally mobile high value manufacturing investments in the UK. The MDMTF will increase the production of medicines and diagnostic equipment in the UK. In doing so, it seeks also to support companies in adopting new technologies which boost productivity, drive down costs and which have less impact on the environment.

The Government will also publish a Life Sciences Vision later this year which will set out our ambition for supporting growth of the life sciences sector, including in manufacturing.

Amanda Solloway
Government Whip, Lord Commissioner of HM Treasury
19th Apr 2021
To ask the Secretary of State for Business, Energy and Industrial Strategy, whether he has allocated any financial or other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace database system.

To date, no financial or other resources have been allocated from the Department of Business, Energy and Industrial Strategy’s (BEIS) budget to investigate potential future uses by the department of the NHS Test and Trace database system.

Amanda Solloway
Government Whip, Lord Commissioner of HM Treasury
19th Apr 2021
To ask the Secretary of State for Business, Energy and Industrial Strategy, whether his Department plans to use the NHS Test and Trace database system.

The corporate functions of the Department do not have access to the NHS Test and Trace database system. The Department therefore does not currently plan to use it.

Amanda Solloway
Government Whip, Lord Commissioner of HM Treasury
4th Feb 2021
To ask the Secretary of State for Business, Energy and Industrial Strategy, what recent assessment he has made of the (a) competitiveness of electricity prices in the UK and (b) effect of those prices on the UK steel sector’s ability to compete internationally.

The Government is committed to minimising energy costs for businesses to ensure our economy remains strong and competitive. The ability for our industries to be able to compete across Europe and globally is a priority for this Government.

The Government has put moving to a cleaner, greener economy at the heart of its Industrial Strategy, especially with our commitment to Net Zero. Our aim is to work with the steel sector and help them to reduce carbon emissions. We will continue to support the steel sector in achieving these aims through the various funds available such as the Industrial Energy Transformation Fund and Clean Steel Fund.

We estimate that reduction in the various renewable costs for eligible energy intensive industries, including steel, will save them around £400m a year in electricity costs. We have also extended the schemes to compensate certain energy intensive industries for indirect emission cost to the end of the next financial year in order to minimise disruption to existing recipients whilst we conduct a review. Between 2013 and 2019, total compensation paid to the steel sector was over £480m.

We welcome the recent report by UK Steel - “Closing the Gap” - regarding electricity prices and will give its recommendations careful consideration.

Nadhim Zahawi
Secretary of State for Education
4th Feb 2021
To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the potential merits of the recommendations made by UK Steel in its February 2021 report, Closing the Gap, on reducing the disparity between the UK and the German and French industrial electricity prices.

We welcome this report and will give its recommendations careful consideration.

Nadhim Zahawi
Secretary of State for Education
4th Feb 2021
To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the potential effect of the Targeted Charging Review proposals on the UK steel sector.

Network charging is a matter for Ofgem, as the independent regulator, and decisions on its Targeted Charging Review (TCR) are for it to make. Through the TCR, Ofgem is seeking to ensure all parties connected to the electricity network make a fair contribution to its fixed costs. This is consistent with Government’s views on the importance of an energy system that ensures a fair distribution of costs, with solutions rewarded where they contribute to reduced system costs.

Ofgem has published an analysis of the expected impacts of the TCR reforms at: https://www.ofgem.gov.uk/electricity/transmission-networks/charging/targeted-charging-review-significant-code-review . Ofgem is working to implement the reforms by April 2022 through code changes, with the final aspects of those code changes being consulted on shortly.

The Government continues to engage with Ofgem to inform our understanding of the reforms’ policy implications, and we will also give careful consideration to the related recommendations of the recent UK Steel report “Closing the Gap”.

Anne-Marie Trevelyan
Secretary of State for International Trade and President of the Board of Trade
4th Feb 2021
To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the potential effect of Ofgem’s proposed reforms under the Targeting Charging Review on costs for steel companies; and what plans Ofgem has to review those proposals.

Network charging is a matter for Ofgem, as the independent regulator, and decisions on its Targeted Charging Review (TCR) are for it to make. Through the TCR, Ofgem is seeking to ensure all parties connected to the electricity network make a fair contribution to its fixed costs. This is consistent with Government’s views on the importance of an energy system that ensures a fair distribution of costs, with solutions rewarded where they contribute to reduced system costs.

Ofgem has published an analysis of the expected impacts of the TCR reforms at: https://www.ofgem.gov.uk/electricity/transmission-networks/charging/targeted-charging-review-significant-code-review . Ofgem is working to implement the reforms by April 2022 through code changes, with the final aspects of those code changes being consulted on shortly.

The Government continues to engage with Ofgem to inform our understanding of the reforms’ policy implications, and we will also give careful consideration to the related recommendations of the recent UK Steel report “Closing the Gap”.

Anne-Marie Trevelyan
Secretary of State for International Trade and President of the Board of Trade
1st May 2020
To ask the Secretary of State for Business, Energy and Industrial Strategy, what steps his Department is taking in addition to Budget 2020 measures to support science funding and R&D tax credits by increasing the incentives for advanced medicines manufacturing in the UK.

The UK has world leading science and research capabilities and we have already committed to utilising these to address the COVID-19 challenges, in close collaboration with the research and business communities in the advanced manufacturing sector.

In April we announced a £1.25 billion package to help ensure innovative firms in some of the most dynamic sectors of the UK economy – including life sciences – are protected through the COVID-19 crisis so they can continue to develop innovative new products. As part of this Innovate UK, part of UK Research and Innovation (UKRI), are investing £750 million to support innovation in the country’s most research-intensive businesses during and post the coronavirus pandemic, and to support new ways of dealing with global disruption. The package will include grants, loans, and expanded business advisory support. This package builds on the government’s existing support for innovative, high-growth firms including the £2.5 billion British Patient Capital fund, the upcoming £200 million Life Sciences Investment Programme, internationally competitive R&D tax reliefs and our major commitments to increase public R&D spending to £22 billion by 2024-25.

Currently over £36 million is awarded through UKRI to projects directly related to tackling Covid-19.? This includes £24.6 million awarded across 27 projects, including for testing a vaccine, developing therapies and improving understanding of how to treat COVID-19, awarded through a Rapid Response call (now closed) run jointly with the?National Institute for Health Research .

We are also supporting the development of a coronavirus vaccine, working to ensure the UK has the manufacturing capability to produce these at the levels the UK needs. This is at the early stages but progressing rapidly. A new cross government vaccines taskforce has been set up, reporting to the Secretaries of State for BEIS and DHSC as well as Sir Patrick Vallance. It brings together government, industry, academics, funding agencies and other partners to make rapid decisions in order to accelerate vaccine development in the UK, working closely with the BioIndustry Association.

This taskforce is reviewing a number of options, including looking at delivering the Vaccines Manufacturing Innovation Centre (VMIC) earlier than the 2022 opening date originally planned. The VMIC was asked to develop a plan for its dramatic acceleration and expansion. As a result the initial phase of the build has now started which is approximately three months ahead of schedule. Further acceleration and expansion options will be presented by the VMIC to the government in due course, and definitive estimates of further time savings will be available at that time.

Amanda Solloway
Government Whip, Lord Commissioner of HM Treasury
26th Oct 2021
To ask the Secretary of State for Digital, Culture, Media and Sport, whether she has received correspondence from the Gambling Commission on a national register of gamblers.

In October 2019, the Gambling Commission issued a challenge to the gambling industry to develop a workable ‘Single Customer View’ solution. The Single Customer View aims to facilitate data sharing between operators so that harm prevention efforts can be improved by measures which prevent disordered gamblers moving to another operator when one intervenes. As set out in its statement of 7 October, the Commission has no plans to mandate a particular single customer view solution at this stage. The next step is for industry to develop and test potential options.

The Gambling Commission has worked closely with the Information Commissioner’s Office to understand how a single customer view can be delivered in compliance with all relevant data protection requirements. The Information Commissioner’s Office recently published a report confirming it should be possible under data protection law for data to be shared safely and securely between online operators to help prevent gambling related harm. However, the report does not comment on how any single customer view should work in practice. We expect the industry to proceed to trial its planned single customer view solution and will continue to monitor developments closely.

The government is reviewing the Gambling Act 2005 to make sure it is fit for the digital age. Our call for evidence included questions on how the consumer data collected by operators could be better deployed and used to support the government’s objectives. We are considering the evidence carefully and aim to publish a white paper outlining any conclusions and proposals for reform in due course.

Chris Philp
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
26th Oct 2021
To ask the Secretary of State for Digital, Culture, Media and Sport, what assessment she has made of the (a) risk to personal data and (b) implications for privacy of the establishment of a national register of gamblers.

In October 2019, the Gambling Commission issued a challenge to the gambling industry to develop a workable ‘Single Customer View’ solution. The Single Customer View aims to facilitate data sharing between operators so that harm prevention efforts can be improved by measures which prevent disordered gamblers moving to another operator when one intervenes. As set out in its statement of 7 October, the Commission has no plans to mandate a particular single customer view solution at this stage. The next step is for industry to develop and test potential options.

The Gambling Commission has worked closely with the Information Commissioner’s Office to understand how a single customer view can be delivered in compliance with all relevant data protection requirements. The Information Commissioner’s Office recently published a report confirming it should be possible under data protection law for data to be shared safely and securely between online operators to help prevent gambling related harm. However, the report does not comment on how any single customer view should work in practice. We expect the industry to proceed to trial its planned single customer view solution and will continue to monitor developments closely.

The government is reviewing the Gambling Act 2005 to make sure it is fit for the digital age. Our call for evidence included questions on how the consumer data collected by operators could be better deployed and used to support the government’s objectives. We are considering the evidence carefully and aim to publish a white paper outlining any conclusions and proposals for reform in due course.

Chris Philp
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
26th Oct 2021
To ask the Secretary of State for Digital, Culture, Media and Sport, what assessment she has made of whether the introduction of a national register of gamblers is a proportionate response to the level of problem gambling.

In October 2019, the Gambling Commission issued a challenge to the gambling industry to develop a workable ‘Single Customer View’ solution. The Single Customer View aims to facilitate data sharing between operators so that harm prevention efforts can be improved by measures which prevent disordered gamblers moving to another operator when one intervenes. As set out in its statement of 7 October, the Commission has no plans to mandate a particular single customer view solution at this stage. The next step is for industry to develop and test potential options.

The Gambling Commission has worked closely with the Information Commissioner’s Office to understand how a single customer view can be delivered in compliance with all relevant data protection requirements. The Information Commissioner’s Office recently published a report confirming it should be possible under data protection law for data to be shared safely and securely between online operators to help prevent gambling related harm. However, the report does not comment on how any single customer view should work in practice. We expect the industry to proceed to trial its planned single customer view solution and will continue to monitor developments closely.

The government is reviewing the Gambling Act 2005 to make sure it is fit for the digital age. Our call for evidence included questions on how the consumer data collected by operators could be better deployed and used to support the government’s objectives. We are considering the evidence carefully and aim to publish a white paper outlining any conclusions and proposals for reform in due course.

Chris Philp
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
26th Oct 2021
To ask the Secretary of State for Digital, Culture, Media and Sport, what assessment she has made of whether the establishment of a national register of gamblers that contains the personal and financial details of members of the public should be debated in the House.

In October 2019, the Gambling Commission issued a challenge to the gambling industry to develop a workable ‘Single Customer View’ solution. The Single Customer View aims to facilitate data sharing between operators so that harm prevention efforts can be improved by measures which prevent disordered gamblers moving to another operator when one intervenes. As set out in its statement of 7 October, the Commission has no plans to mandate a particular single customer view solution at this stage. The next step is for industry to develop and test potential options.

The Gambling Commission has worked closely with the Information Commissioner’s Office to understand how a single customer view can be delivered in compliance with all relevant data protection requirements. The Information Commissioner’s Office recently published a report confirming it should be possible under data protection law for data to be shared safely and securely between online operators to help prevent gambling related harm. However, the report does not comment on how any single customer view should work in practice. We expect the industry to proceed to trial its planned single customer view solution and will continue to monitor developments closely.

The government is reviewing the Gambling Act 2005 to make sure it is fit for the digital age. Our call for evidence included questions on how the consumer data collected by operators could be better deployed and used to support the government’s objectives. We are considering the evidence carefully and aim to publish a white paper outlining any conclusions and proposals for reform in due course.

Chris Philp
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
26th Oct 2021
To ask the Secretary of State for Digital, Culture, Media and Sport, whether the Gambling Commission is planning to create a national register of gamblers.

In October 2019, the Gambling Commission issued a challenge to the gambling industry to develop a workable ‘Single Customer View’ solution. The Single Customer View aims to facilitate data sharing between operators so that harm prevention efforts can be improved by measures which prevent disordered gamblers moving to another operator when one intervenes. As set out in its statement of 7 October, the Commission has no plans to mandate a particular single customer view solution at this stage. The next step is for industry to develop and test potential options.

The Gambling Commission has worked closely with the Information Commissioner’s Office to understand how a single customer view can be delivered in compliance with all relevant data protection requirements. The Information Commissioner’s Office recently published a report confirming it should be possible under data protection law for data to be shared safely and securely between online operators to help prevent gambling related harm. However, the report does not comment on how any single customer view should work in practice. We expect the industry to proceed to trial its planned single customer view solution and will continue to monitor developments closely.

The government is reviewing the Gambling Act 2005 to make sure it is fit for the digital age. Our call for evidence included questions on how the consumer data collected by operators could be better deployed and used to support the government’s objectives. We are considering the evidence carefully and aim to publish a white paper outlining any conclusions and proposals for reform in due course.

Chris Philp
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
15th Apr 2021
To ask the Secretary of State for Digital, Culture, Media and Sport, what discussions he has had with Cabinet colleagues on using the NHS Test and Trace database system.

No such discussions have taken place. No assessment has yet been made, nor any decisions made, on whether to use the data systems used by NHS Test and Trace for other purposes beyond those related to Covid-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

15th Apr 2021
To ask the Secretary of State for Digital, Culture, Media and Sport, whether his Department plans to use the NHS Test and Trace database system.

No such discussions have taken place. No assessment has yet been made, nor any decisions made, on whether to use the data systems used by NHS Test and Trace for other purposes beyond those related to Covid-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

15th Apr 2021
To ask the Secretary of State for Digital, Culture, Media and Sport, whether he has allocated any financial or other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace database system.

No such discussions have taken place. No assessment has yet been made, nor any decisions made, on whether to use the data systems used by NHS Test and Trace for other purposes beyond those related to Covid-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

14th Apr 2021
To ask the Secretary of State for Digital, Culture, Media and Sport, with reference to the planned hosting of (a) the semi-final and final of the UEFA Euro 2020 football tournament and (b) other major football tournaments, whether (i) Wembley stadium and (ii) other football stadiums will be designated as vital national infrastructure under covid-19 legislation.

Public safety is our main priority and decisions will be guided by a Science Board of relevant experts including senior PHE representation, who will take into account the latest public health data. Matters concerning the national infrastructure are for the Cabinet Office.

Nigel Huddleston
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
14th Apr 2021
To ask the Secretary of State for Digital, Culture, Media and Sport, if he will bring forward proposals to classify sporting and cultural venues as vital national infrastructure under schedule 22 of the Coronavirus Act 2020.

The Government has no current plans to revise the list of sectors designated as critical national infrastructure.

Schedule 22 of the Coronavirus Act 2020 confers powers to the Secretary of State to prohibit or restrict events or gatherings in England. This includes imposing restrictions on the persons entering or remaining on the premises.These regulations are not applicable to any changes in the list of sectors designated as critical national infrastructure.

The government has worked to protect cultural and sporting venues during the lockdown to save sports facilities, theatres, concert halls and live music performance venues for future generations. In July 2020, MHCLG announced changes to the planning system to protect buildings that are an intrinsic part of our cultural heritage. This move was announced alongside the £1.57 billion investment to protect Britain’s cultural, arts and heritage sector and provide extra security to businesses as they plan to reopen their premises when it is safe to do so.

The government has also provided £1.8 billion of public support to the sport sector in response to the pandemic to ensure facilities are able to reopen when it is safe for them to do so.

Nigel Huddleston
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
2nd Dec 2020
To ask the Secretary of State for Digital, Culture, Media and Sport, what assessment he has made of the rate of covid-19 transmission within bowling centres.

Since 2 December, as set out in the COVID Winter Plan, we have returned to a tiered approach to COVID-19 restrictions in England. Relevant venues in the entertainment, leisure and tourism sectors - including bowling alleys - will be permitted to reopen in tiers 1 and 2, subject to curfew restrictions and in line with COVID-19 Secure guidance. In tier 3 areas, indoor venues and attractions - including bowling alleys - must close.

We worked closely with a range of visitor economy stakeholders to develop our guidance for leisure and hospitality venues. We continue to engage with bowling stakeholders, such as the Ten-Pin Bowling Proprietor’s Association, to update and review our guidance. Further specific guidance on bowling alleys has been published within UKHospitality’s ‘COVID-19 Secure Guidelines for Hospitality Businesses.’

Our decisions have been and will continue to be based on scientific evidence and public health assessments.

Bowling centre operators can continue to access the Government’s comprehensive support package - including the extended furlough and self-employed support schemes, new grant schemes, as well as various government-backed loans. We have also provided business rates relief and grants for many in the retail, leisure and hospitality sector.

We are listening to stakeholders’ concerns, and will continue to closely monitor the ongoing impact of Government restrictions on bowling alleys.

Nigel Huddleston
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
2nd Dec 2020
To ask the Secretary of State for Digital, Culture, Media and Sport, what steps his Department is taking to support operators of bowling centres during their extended period of closure during the covid-19 outbreak.

Since 2 December, as set out in the COVID Winter Plan, we have returned to a tiered approach to COVID-19 restrictions in England. Relevant venues in the entertainment, leisure and tourism sectors - including bowling alleys - will be permitted to reopen in tiers 1 and 2, subject to curfew restrictions and in line with COVID-19 Secure guidance. In tier 3 areas, indoor venues and attractions - including bowling alleys - must close.

We worked closely with a range of visitor economy stakeholders to develop our guidance for leisure and hospitality venues. We continue to engage with bowling stakeholders, such as the Ten-Pin Bowling Proprietor’s Association, to update and review our guidance. Further specific guidance on bowling alleys has been published within UKHospitality’s ‘COVID-19 Secure Guidelines for Hospitality Businesses.’

Our decisions have been and will continue to be based on scientific evidence and public health assessments.

Bowling centre operators can continue to access the Government’s comprehensive support package - including the extended furlough and self-employed support schemes, new grant schemes, as well as various government-backed loans. We have also provided business rates relief and grants for many in the retail, leisure and hospitality sector.

We are listening to stakeholders’ concerns, and will continue to closely monitor the ongoing impact of Government restrictions on bowling alleys.

Nigel Huddleston
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
12th Nov 2020
To ask the Secretary of State for Digital, Culture, Media and Sport, what assessment his Department has made of the economic benefit of the contribution made by church buildings used for community purposes.

Many places of worship do accommodate additional uses, including those for community purposes, alongside worship. These buildings provide economic and social positive externalities to the country as a whole, and at a local level, they provide a thriving community asset. Places of worship forge social capital by strengthening community cohesion and belonging, alongside providing significant social benefits in times of need. Social action at places of worship is equally prevalent and valuable, such as food banks, blood donation centres and night shelters.

The Government has set out its vision and strategy to protect the historic environment, including England’s places of worship, in the 2017 Heritage Statement. The DCMS-funded Taylor Review Pilot, and its subsequent evaluation, published in October 2020, underlines the importance of a strategic approach, based on understanding the gaps in local community provision, when considering additional uses of places of worship.

Nigel Huddleston
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
10th Nov 2020
To ask the Secretary of State for Digital, Culture, Media and Sport, whether he plans to allocate funding to churches for the maintenance of church buildings as a result of their contribution to the provision of public services.

Many places of worship do accommodate additional uses, including those for community purposes, alongside worship. These buildings provide economic and social positive externalities to the country as a whole, and at a local level, they provide a thriving community asset. Places of worship forge social capital by strengthening community cohesion and belonging alongside providing significant social benefits in times of need. Social action at places of worship is equally prevalent and valuable, such as food banks, blood donation centres and night shelters.

The Government has set out its vision and strategy to protect the historic environment, including England’s places of worship, in the 2017 Heritage Statement. The DCMS-funded Taylor Review Pilot and its subsequent evaluation, published in October 2020, underlines the importance of a strategic approach, based on understanding the gaps in local community provision, when considering additional uses of places of worship.

The Government has supported the maintenance of historic churches throughout the UK since 2001 through the Listed Places of Worship Grant Scheme. The Scheme, which is currently funded until the end of March 2021, provides grants towards VAT paid on repairs and maintenance. It presently handles around 7000 claims per annum, is open to all faiths and denominations and is delivered UK wide.

In addition, in response to the Covid-19 pandemic, the Government has announced significant cross-sector support. This includes a £1.57 billion Cultural Recovery Fund announced earlier this summer, aimed at helping key cultural organisations, including places of worship, through the pandemic. The fund represents the biggest ever one-off investment in UK culture, complementing the Covid-19 support schemes launched earlier in the year by Historic England and the National Lottery Heritage Fund.

Any extension to the existing funding is subject to the Spending Review, which is due to conclude later this month.

Nigel Huddleston
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
10th Nov 2020
To ask the Secretary of State for Digital, Culture, Media and Sport, what recent assessment he has made of the (a) economic and (b) social effect of using church buildings for cultural and entertainment purposes.

Many places of worship do accommodate additional uses, including those for social support, cultural and entertainment purposes, alongside worship. These buildings provide economic and social positive externalities to the country as a whole, and at a local level, they provide a thriving community asset. Places of worship forge social capital by strengthening community cohesion and belonging alongside providing significant social benefits in times of need. Social action at places of worship is equally prevalent and valuable, such as food banks, blood donation centres and night shelters.

The Government has set out its vision and strategy to protect the historic environment, including England’s places of worship, in the 2017 Heritage Statement. The DCMS-funded Taylor Review Pilot and its subsequent evaluation underlines the importance of a strategic approach, based on understanding the gaps in local community provision, when considering additional uses of places of worship.

Nigel Huddleston
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
16th Apr 2021
To ask the Secretary of State for Education, what discussions he has had with Cabinet colleagues on future uses of the NHS Test and Trace database system.

NHS Test and Trace data is used by the Department for Education to routinely monitor and report to Ministers on the take-up of COVID-19 testing in schools and colleges, and to support operational delivery. For example, the Department has used the data to proactively identify schools that required additional support to report test results for their setting during the initial on-site testing phase of the programme.

16th Apr 2021
To ask the Secretary of State for Education, whether his Department has plans to use the NHS Test and Trace database system.

NHS Test and Trace data is used by the Department for Education to routinely monitor and report to Ministers on the take-up of COVID-19 testing in schools and colleges, and to support operational delivery. For example, the Department has used the data to proactively identify schools that required additional support to report test results for their setting during the initial on-site testing phase of the programme.

16th Apr 2021
To ask the Secretary of State for Education, whether he has allocated (a) financial and (b) other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace system.

NHS Test and Trace data is used by the Department for Education to routinely monitor and report to Ministers on the take-up of COVID-19 testing in schools and colleges, and to support operational delivery. For example, the Department has used the data to proactively identify schools that required additional support to report test results for their setting during the initial on-site testing phase of the programme.

10th Dec 2020
To ask the Secretary of State for Education, how many times on average pupils in (a) Bolton, (b) Wigan, (c) the county of Cornwall and (d) Greater London were sent home from school due to covid-19 in (i) September, (ii) October and (iii) November 2020.

The Department collects data on the number of schools that have indicated they have sent children home due to COVID-19 containment on a daily basis, as well as the total number of pupils in attendance and the number of pupils asked to isolate due to potential contact with COVID-19. This data is published from this collection at both national and local authority levels as part of the official statistics series. The publication can be found here: https://explore-education-statistics.service.gov.uk/find-statistics/attendance-in-education-and-early-years-settings-during-the-coronavirus-covid-19-outbreak. Data is published from 9 September 2020, but prior to 12 October 2020 information on pupils isolating was not collected. This data is collected at school level, not pupil level. Therefore, we cannot estimate the average number of times a pupil has been asked to isolate.

The Department is constantly reviewing the content of its publications. Announcements about future content will be made through the official statistics release page: https://www.gov.uk/government/organisations/department-for-education/about/statistics.

7th Sep 2020
What steps his Department is taking to support good (a) attendance and (b) behaviour as pupils return to school as covid-19 restrictions are eased.

It is vital for all pupils to return to school to minimise the impact of the pandemic on their education. It is important for schools to also be calm and disciplined environments, where everyone follows the rules.

We have published guidance for school leaders to support them to:

  • communicate clear and consistent expectations around school attendance to families throughout the summer ahead of the new school year
  • identify pupils who are reluctant or anxious about returning or who are at risk of disengagement and develop plans for re-engaging them using the additional catch-up funding schools will receive
  • work closely with other professionals as appropriate to support the return to school, including social workers and other specialist services
  • update behaviour policies and communicate any new rules clearly and consistently to staff, pupils and parents
  • ensure appropriate provision is in place for pupils with additional needs. Some children will return to school having been exposed to a range of adversity which may lead to social, emotional and mental health concerns.

To support this work on the ground, regional teams continue to engage regularly with local authorities to understand any barriers to attendance. We are also working with stakeholders to enable schools and LAs to share best practice to improve attendance and ensure a smooth transition back to school.

More widely, we are running a ‘Back to school’ campaign which seeks to reassure parents and explain the measures that education providers are taking to reduce the risk of transmission.

We have also worked with local authorities and transport providers to make sure children/young people can get to school/college safely, providing more than £40 million of additional funding to create extra capacity.

The Department will shortly be inviting schools with exemplary behaviour to deliver the Behaviour Hubs programme and support those schools that need additional support in turning around their behaviour cultures. Over the Autumn term, National Leaders of Education will continue to work with schools most affected by COVID-19, including in improving behaviour.

18th Mar 2020
To ask the Secretary of State for International Development, what recent representations she has made to the Palestinian Authority on reports that three schools are named after Nazi collaborators.

We have raised our concerns about school naming at senior levels within the Palestinian Authority (PA) and will continue to do so. Our partnership with the PA includes a commitment from the Palestinian leadership to adhere to the principle of non-violence and to tackle language and actions that could incite violence or hatred. We continue to assess that the PA’s commitment to peace is in line with our Partnership Principles.

UK support to the PA contributes to the salaries of carefully vetted teachers and education workers in the West Bank through the Palestinian-European Socio-Economic Management Assistance mechanism, which screens recipients against international sanctions lists.

James Cleverly
Minister of State (Foreign, Commonwealth and Development Office)
25th Nov 2020
To ask the Secretary of State for International Trade, what level of tariff will be introduced by the UK Global Tariff regime on medical products such as adhesive removal sprays and the medical devices which require their use in the event that the UK leaves the EU without a deal.

Our ambition is to ensure there are no tariffs, fees, charges or quantitative restrictions on trade in goods between the UK and the European Union (EU) at the end of the transition period through a Free Trade Agreement (FTA). We are currently in an intense phase of negotiations with the EU, and we are working hard to achieve that. We therefore do not expect the UK Global Tariff (UKGT) to apply to EU imports.

The UKGT will apply to UK imports from countries the UK does not have trading arrangements in place with. The Government has assessed all available evidence submitted as a part of the public consultation in depth, and in addition, conducted its own assessment to ensure the UKGT is robust and supportive of the UK’s economy. Government will publish more analysis in the Tax Information and Impact Note (TIIN) alongside the legislation, as is standard practice.

Greg Hands
Minister of State (Department for Business, Energy and Industrial Strategy)
25th Nov 2020
To ask the Secretary of State for International Trade, what assessment she has made of the effect on charges to patients of the introduction of tariffs on medical products such as adhesive removal sprays and the medical devices which require their use in the event that the UK leaves the EU without a deal; which other essential products will potentially be subject to such tariffs; and if she will make a statement.

Our ambition is to ensure there are no tariffs, fees, charges or quantitative restrictions on trade in goods between the UK and the European Union (EU) at the end of the transition period through a Free Trade Agreement (FTA). We are currently in an intense phase of negotiations with the EU, and we are working hard to achieve that. We therefore do not expect the UK Global Tariff (UKGT) to apply to EU imports.

The UKGT will apply to UK imports from countries the UK does not have trading arrangements in place with. The Government has assessed all available evidence submitted as a part of the public consultation in depth, and in addition, conducted its own assessment to ensure the UKGT is robust and supportive of the UK’s economy. Government will publish more analysis in the Tax Information and Impact Note (TIIN) alongside the legislation, as is standard practice.

Greg Hands
Minister of State (Department for Business, Energy and Industrial Strategy)
12th May 2020
What steps her Department is taking to protect the global supply chains of UK businesses.

The Department is working to reduce market access barriers, including through Free Trade Agreements. This will open up more opportunities for business to build further resilience into their supply chains for the future. Alongside this, the United Kingdom will tirelessly fight protectionism and unfair trade practices, including through the G20 and in the WTO.

The United Kingdom has strong, collaborative relationships with other countries on this international endeavour, and will continue to make progress to facilitate free flowing trade. This will continue to be vital throughout the COVID-19 crisis, and for the recovery that will follow.

Ranil Jayawardena
Parliamentary Under-Secretary (Department for International Trade)
19th Apr 2021
To ask the Secretary of State for Transport, what discussions he has had with Cabinet colleagues on using the NHS Test and Trace database system.

The Department fully supports the NHS Test and Trace system and has been investigating ways that the system can be used on the transport network to play its part in tackling Covid-19. We have been working closely with the Department for Health and Social Care to understand how best the system can be used going forward. Some areas across the Departmental Group have already introduced using QR codes within their public only areas. Currently, the Department has not needed to allocate any financial resource from its budget. However, as policy and the technology develops, this will be kept under review. It is also worth noting that Test and Trace data will only be used to tackle Covid and won’t be used for other purposes.

Chris Heaton-Harris
Minister of State (Department for Transport)
19th Apr 2021
To ask the Secretary of State for Transport, whether his Department plans to use the NHS Test and Trace database system.

The Department fully supports the NHS Test and Trace system and has been investigating ways that the system can be used on the transport network to play its part in tackling Covid-19. We have been working closely with the Department for Health and Social Care to understand how best the system can be used going forward. Some areas across the Departmental Group have already introduced using QR codes within their public only areas. Currently, the Department has not needed to allocate any financial resource from its budget. However, as policy and the technology develops, this will be kept under review. It is also worth noting that Test and Trace data will only be used to tackle Covid and won’t be used for other purposes.

Chris Heaton-Harris
Minister of State (Department for Transport)
19th Apr 2021
To ask the Secretary of State for Transport, whether he has allocated any financial or other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace database system.

The Department fully supports the NHS Test and Trace system and has been investigating ways that the system can be used on the transport network to play its part in tackling Covid-19. We have been working closely with the Department for Health and Social Care to understand how best the system can be used going forward. Some areas across the Departmental Group have already introduced using QR codes within their public only areas. Currently, the Department has not needed to allocate any financial resource from its budget. However, as policy and the technology develops, this will be kept under review. It is also worth noting that Test and Trace data will only be used to tackle Covid and won’t be used for other purposes.

Chris Heaton-Harris
Minister of State (Department for Transport)
19th Apr 2021
To ask the Secretary of State for Transport, what assessment his Department has made of the potential effect of covid-19 passports on the ability of people who identify as (a) Black-Caribbean, (b) Black-African and (c) South Asian to travel internationally.

Work on developing vaccine certification for international travel continues. We will continue to work across government to consider any potential effects as the policy progresses.

Robert Courts
Parliamentary Under-Secretary (Department for Transport)
19th Apr 2021
To ask the Secretary of State for Work and Pensions, whether she plans to work with the NHS Test and Trace database system.

No assessment has yet been made, nor any decisions made, on whether to use the data systems used by NHS Test and Trace for other purposes beyond those related to Covid-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Guy Opperman
Parliamentary Under-Secretary (Department for Work and Pensions)
19th Apr 2021
To ask the Secretary of State for Work and Pensions, if any financial or other resource allocation has been made to investigate the possibility of how her Department can make use of the NHS Test and Trace database system.

No assessment has yet been made, nor any decisions made, on whether to use the data systems used by NHS Test and Trace for other purposes beyond those related to Covid-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Guy Opperman
Parliamentary Under-Secretary (Department for Work and Pensions)
16th Apr 2021
To ask the Secretary of State for Work and Pensions, what discussions she has had with Cabinet colleagues on future uses of the NHS Test and Trace database system.

No such discussions have taken place.

Guy Opperman
Parliamentary Under-Secretary (Department for Work and Pensions)
10th Nov 2020
To ask the hon. Member for South West Bedfordshire, representing the Church Commissioners, what assessment the Commissioners have made of the effect of churches on community health and wellbeing through their provision of food banks, youth services, mental health services, addiction support services and other community services during the covid-19 outbreak and associated lockdowns.

The parish church is a key source of community support and I commend the work of clergy and volunteers across the country during this very challenging time.

Recent research published by Theos and the Church Urban Fund https://www.theosthinktank.co.uk/cmsfiles/GRACE-CUF-v10-combined.pdf and separately by the National Churches Trust https://www.houseofgood.nationalchurchestrust.org/ has shown the substantial social and economic contribution parishes, and cathedrals make to their local communities.

Across the dioceses of the Church of England churches are operating 35,000 based projects which serve the needs of their communities, I am pleased to say that many of these have continued to operate during the pandemic within the guidelines set out by Government on Covid-19, providing crisis support such as foodbanks, bereavement counselling, night shelters, debt relief advice, as well as project work to combat modern slavery and support victim of domestic abuse.

Andrew Selous
Second Church Estates Commissioner
5th Nov 2021
To ask the Secretary of State for Health and Social Care, what steps he is taking to help tackle the policy and system barriers NICE has flagged as preventing the implementation of the discount rate in their Methods and Process Review.

The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for its methods and processes. NICE recently consulted on proposals for changes to its methods and processes, including the discount rate, and is now carefully considering the comments received.

NICE’s consultation stated that there is an evidence-based case for changing the reference case discount rate to 1.5% but acknowledged the wider policy and fiscal implications and proposed further consideration of changing the discount rate through wider policy discussions. NICE also proposed to maintain a non-reference case discount rate of 1.5% for use in exceptional circumstances.

The Government will take NICE’s findings into account in due course.

Edward Argar
Minister of State (Department of Health and Social Care)
5th Nov 2021
To ask the Secretary of State for Health and Social Care, what assessment he has made of progress in (a) improving patients' access to new medicines and (b) meeting the UK's ambitions to be a global life sciences hub in response to the recommendations arising from the NICE Methods Review; and if he will make a statement.

The Government is committed to ensuring patients can access clinically and cost-effective new medicines. The National Institute for Health and Care Excellence (NICE) appraises the clinical and cost effectiveness of all new medicines and National Health Service organisations are legally required to fund medicines recommended by NICE, normally within three months of the publication of final guidance. NICE recommends the vast majority of new medicines for routine use on the NHS and many thousands of patients have benefited from access to effective new medicines as a result.

NICE consulted on a range of proposed changes to its methods earlier this year as part of the ongoing review of its methods and processes for health technology assessment. The methods and process review will ensure that NICE retains global leadership in the evaluation and appraisal of new medicines and technologies. As reflected in the Life Sciences Vision, this will support the Government’s ambition to make the UK the best place in the world to develop, trial, launch and adopt innovative new medicines, improving patient access to medicines.

Edward Argar
Minister of State (Department of Health and Social Care)
20th Oct 2021
To ask the Secretary of State for Health and Social Care, how many gene and cell therapies have been appraised by NICE through a Single Technology Appraisal; and what category of recommendation made in each of those cases was (a) recommended, (b) optimised, (c) Cancer Drugs Fund, (d) not recommended and (e) only in research.

As of October 2021, the National Institute for Health and Care Excellence (NICE) has published technology appraisals guidance on seven gene and cell therapies. The following table shows NICE’s recommendation for each cell and gene therapy.

Technology

Categorisation

Talimogene laherparepvec

Optimised

Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells)

Optimised

Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells)

Only in Research

Autologous chondrocyte implantation using chondrosphere

Optimised

Tisagenlecleucel

Recommended (Cancer Drugs Fund)

Darvadstrocel

Not recommended

Axicabtagene ciloleucel

Recommended (Cancer Drugs Fund)

Tisagenlecleucel

Recommended (Cancer Drugs Fund)

Edward Argar
Minister of State (Department of Health and Social Care)
20th Oct 2021
To ask the Secretary of State for Health and Social Care, how much funding was allocated to the NHS Genomic Medicine Service in the most recent financial year for which data is available.

The seven National Health Service Genomic Laboratory Hubs (GLHs) are commissioned by NHS England and NHS Improvement. The information requested on the budget for each GLH and funding allocated to the NHS Genomic Medicine Service is not held in the format requested. While NHS England and NHS Improvement allocate some resources through specialised commissioning and highly specialised services, funding is also provided through local commissioning budgets which is not held centrally.

The National Genomic Test Directory currently covers over 3,000 rare and inherited diseases and the majority of solid and haematological cancers. The national genomic testing strategy focuses on implementing comprehensive DNA and RNA testing through to a full repertoire of genomic testing up to the level of whole exome and whole genome sequencing to drive efficiency and productivity. The National Genomic Test Directory is reviewed on an annual basis to keep pace with scientific, clinical and technological advances, while delivering value for money for the NHS. The strategic approach of the NHS Genomic Medicine Service is also informed by the NHS Long Term Plan and the Government’s strategy for healthcare genomics, Genome UK.

Maria Caulfield
Parliamentary Under-Secretary (Department of Health and Social Care)
20th Oct 2021
To ask the Secretary of State for Health and Social Care, what the (a) budget and (b) testing strategy are for each genomic laboratory hub for the most recent year for which data is available.

The seven National Health Service Genomic Laboratory Hubs (GLHs) are commissioned by NHS England and NHS Improvement. The information requested on the budget for each GLH and funding allocated to the NHS Genomic Medicine Service is not held in the format requested. While NHS England and NHS Improvement allocate some resources through specialised commissioning and highly specialised services, funding is also provided through local commissioning budgets which is not held centrally.

The National Genomic Test Directory currently covers over 3,000 rare and inherited diseases and the majority of solid and haematological cancers. The national genomic testing strategy focuses on implementing comprehensive DNA and RNA testing through to a full repertoire of genomic testing up to the level of whole exome and whole genome sequencing to drive efficiency and productivity. The National Genomic Test Directory is reviewed on an annual basis to keep pace with scientific, clinical and technological advances, while delivering value for money for the NHS. The strategic approach of the NHS Genomic Medicine Service is also informed by the NHS Long Term Plan and the Government’s strategy for healthcare genomics, Genome UK.

Maria Caulfield
Parliamentary Under-Secretary (Department of Health and Social Care)
20th Oct 2021
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of the cost neutral approach taken in the proposals for change to NICE methods and process in the context of the Voluntary Pricing and Access Scheme agreement which commits industry to pay back any growth in the medicines budget above the agreed level.

The National Institute for Health and Care Excellence (NICE) is an independent body responsible for the review of its methods and processes. The Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) states that NICE’s methods review should be consistent with improving the health gain achieved by spending on new innovative medicines, meaning that the proposals should result in the same or lower prices for new medicines on average. Whilst the VPAS aims to contribute to maintaining affordability of overall National Health Service spending on branded medicines, it not the only mechanism for doing so. The financial impact of any changes to NICE’s methods and processes will extend beyond the life of the current VPAS and NICE considers the budgetary impact of its proposals.

Edward Argar
Minister of State (Department of Health and Social Care)
23rd Sep 2021
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access for patients to new techniques for tackling heart valve disease.

NHS England and NHS Improvement evaluate new technology and the commissioning of newer techniques in tackling heart valve disease as it becomes available. This has led to improvements for patients in accessing new surgical heart valves such as sutureless valve replacement and for mitral valve leaflet repair. NHS England and NHS Improvement are increasing availability to mitral valve repair through commissioning local centres to deliver this procedure, working to their own prioritised timetable. A number of specialised heart valve devices and procedures are being taken through the evaluation process to ensure an appropriate evidenced-based approach to commissioning new technologies and techniques.

Maria Caulfield
Parliamentary Under-Secretary (Department of Health and Social Care)
23rd Sep 2021
To ask the Secretary of State for Health and Social Care, what comparative assessment his Department has made of the cost-saving benefits of (a) mitral valve repair and (b) open heart surgery.

No such assessment has been made, as there is no direct comparison between mitral valve leaflet repair and conventional open heart surgery. Patients must be assessed by clinicians as inoperable or very high risk to undergo mitral valve repair and the procedure would be expected to provide sustained quality of life benefits.

Maria Caulfield
Parliamentary Under-Secretary (Department of Health and Social Care)
23rd Sep 2021
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of aligning the treatment pathway for heart valve disease with the pathways indicated by recent international evidence.

NHS England and NHS Improvement assess treatment pathways for heart valve disease using the best evidence available, including international evidence and advice from the National Institute for Health and Care Excellence.

Maria Caulfield
Parliamentary Under-Secretary (Department of Health and Social Care)
22nd Jul 2021
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the implications for its policies of the US Food & Drug Administration Safety Communication entitled Flexible Bronchoscopes and Updated Recommendations for Reprocessing, issued on June 25th, 2021; and what discussions he has had with (a) his US counterpart, (b) the Medicines and Healthcare Products Regulatory Agency and (c) relevant stakeholders on the potential implementation of US FDA recommendations in the UK.

There are currently no plans to implement the United States Food and Drug Administration’s (FDA) recommendations in the United Kingdom. The Medicines and Healthcare products Regulatory Agency (MHRA) is aware of the FDA’s ‘Flexible Bronchoscopes and Updated Recommendations for Reprocessing: FDA Safety Communication’, issued on 25 June 2021. While there have been no specific discussions the FDA’s recommendations broadly align to the UK guidelines and work practices set out in ‘Management and decontamination of flexible endoscopes’ Health Technical Memorandum, published in 2016 and regularly updated.

Edward Argar
Minister of State (Department of Health and Social Care)
16th Jul 2021
To ask the Secretary of State for Health and Social Care, whether he plans to publish (a) a report or (b) the research data that was used to impose the mandatory requirement for people to wear face coverings in June 2020 during the covid-19 outbreak.

On 21 April 2020, the Scientific Advisory Group for Emergencies (SAGE) advised that there was enough evidence to recommend that the public wear cloth face masks when in enclosed spaces where social distancing is not possible. In making its recommendations to the Government, SAGE considered the evidence from a number of different studies and their conclusions are available at the following link:

https://www.gov.uk/government/publications/sage-minutes-coronavirus-covid-19-response-21-april-2020

In June 2020, Public Health England (PHE) used an established methodology to complete a rapid review of the evidence related to face coverings in the community and COVID-19 and concluded that “the beneficial effects of wearing masks may be increased when combined with other non-pharmaceutical interventions, such as hand washing and social distancing.” A second review, published in January 2021, found evidence consistent with the findings of the first review, that the use of face coverings in the community helped reduce the spread of COVID-19. Therefore, PHE continue to advocate the same measures of wearing face coverings in specified community settings, alongside social distancing and good hand hygiene.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
28th Jun 2021
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the changes needed to (a) NICE and NHS England and Improvement's health technology approval processes and (b) NHS England's commercial policy to improve (i) access to and (ii) uptake of new medicines and vaccines; and if he will make a statement.

The National Institute of Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE is responsible for the methods and processes it uses in the assessment of health technologies and it is currently reviewing its appraisal methods.

New commercial flexibilities and support structures have been introduced to support access and uptake of transformative medicines, including NHS England and NHS Improvement’s Commercial Framework.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
28th Jun 2021
To ask the Secretary of State for Health and Social Care, what assessment he has made of progress in improving patients' access to new medicines in response to the recommendations of the case for change arising from the NICE Methods Review; and if he will make a statement.

The National Institute for Health and Care Excellence (NICE) now aims to publish draft recommendations on all newly licensed treatments around the time of licensing with final guidance within 90 days of marketing authorisation wherever possible. NICE also recommends the vast majority of new medicines that it appraises for some or all of the eligible patient population.

NICE’s review of its methods and processes is ongoing. The purpose of the review is to ensure that NICE’s methods and processes support the National Health Service to provide high quality care and value for money. NICE consulted on proposals for the case for change in late 2020. NICE expects to consult on the draft programme manual in the summer, with implementation of the changes from early 2022.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
8th Jun 2021
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that unlicensed cannabis-based products for medicinal use prescribed in the UK, either privately or on the NHS, are subject to robust standards of (a) safety, (b) quality and (c) efficacy.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medicines in the United Kingdom and continues to provide scientific and regulatory advice to any company at any stage of product development to support companies intending to apply for clinical trials authorisations or marketing authorisations. However, the MHRA cannot solicit applications.

The Department has called on industry to invest in clinical trials and subject their products to full scrutiny by the regulators. To stimulate research proposals, the National Institute of Health Research (NIHR) has issued two calls for research into cannabis-based products for medicinal use and has taken steps to advertise the call to all manufacturers interested in supplying the UK market. The NIHR also remain open to the submission of proposals outside of these specific calls.

The vast majority of cannabis-based products for medicinal use are unlicensed medicines and have not had their safety, quality or efficacy assured by the MHRA, nor their cost-effectiveness determined by the National Institute for Health and Care Excellence. However, any unlicensed medicines manufactured in or imported into the UK must be manufactured to Good Manufacturing Practice standards. This is assured through licensing processes and import controls.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
8th Jun 2021
To ask the Secretary of State for Health and Social Care, what steps he is taking to encourage companies to (a) collect high-quality evidence through randomised control trials and (b) pursue regulatory approval for cannabis-based medicinal products.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medicines in the United Kingdom and continues to provide scientific and regulatory advice to any company at any stage of product development to support companies intending to apply for clinical trials authorisations or marketing authorisations. However, the MHRA cannot solicit applications.

The Department has called on industry to invest in clinical trials and subject their products to full scrutiny by the regulators. To stimulate research proposals, the National Institute of Health Research (NIHR) has issued two calls for research into cannabis-based products for medicinal use and has taken steps to advertise the call to all manufacturers interested in supplying the UK market. The NIHR also remain open to the submission of proposals outside of these specific calls.

The vast majority of cannabis-based products for medicinal use are unlicensed medicines and have not had their safety, quality or efficacy assured by the MHRA, nor their cost-effectiveness determined by the National Institute for Health and Care Excellence. However, any unlicensed medicines manufactured in or imported into the UK must be manufactured to Good Manufacturing Practice standards. This is assured through licensing processes and import controls.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
24th May 2021
To ask the Secretary of State for Health and Social Care, how the NHS plans to tackle (a) the current backlog in cancer diagnosis and (b) ensure that any additional referrals for diagnosis are not delayed.

The National Health Service priorities and operational planning guidance 2021/22 sets out how the NHS aims to tackle the backlog in cancer treatment which includes:

- Increasing people with symptoms coming forward through cancer-specific messages as part of the ‘Help Us Help You’ campaign;

- Rapidly increasing diagnostic capacity, with immediate action plans to increase endoscopy and computed tomography capacity; and

- Focusing on reducing the number of patients waiting over 62-days on cancer pathways, rescheduling diagnostic procedures or treatment for those who have had their care delayed by the pandemic.

Local health systems, drawing on advice and analysis from their Cancer Alliance, will ensure that there is sufficient diagnostic and treatment capacity in place to meet cancer need to ensure that any additional referrals for diagnosis are not delayed.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
24th May 2021
To ask the Secretary of State for Health and Social Care, how the forthcoming NHS Bill will support patients' ability to receive the most effective therapeutic innovations as early as possible in their treatment.

The upcoming Health and Social Care Bill will build on the work of the National Health Service to support integration, joint working and the delivery of the NHS Long Term Plan.

It will put integrated care systems on a statutory footing focusing resources on effective treatments and innovations and working to streamline referral and patient pathways as far as possible. This will support the NHS to deliver the most effective therapeutic innovations as early as possible.

Edward Argar
Minister of State (Department of Health and Social Care)
20th Apr 2021
To ask the Secretary of State for Health and Social Care, how long lateral flow tests for Covid-19 will remain free to members of the public.

From 9 April everyone in England has been able to access free COVID-19 testing and there are currently no plans to end free testing using lateral flow devices.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
15th Apr 2021
To ask the Secretary of State for Health and Social Care, whether his Department plans to use the NHS Test and Trace database system.

No assessment or decisions have yet been made on the use of NHS Test and Trace data systems for other purposes beyond those related to COVID-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
15th Apr 2021
To ask the Secretary of State for Health and Social Care, whether he has allocated any financial or other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace database system.

No assessment or decisions have yet been made on the use of NHS Test and Trace data systems for other purposes beyond those related to COVID-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
15th Apr 2021
To ask the Secretary of State for Health and Social Care, what discussions he has had with Cabinet colleagues on future use by his Department of the NHS Test and Trace database system.

No such discussions have taken place.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential for the NHS Test and Trace database system to have wider uses beyond its current application.

No assessment or decisions have yet been made on the use of NHS Test and Trace data systems for other purposes beyond those related to COVID-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, how much funding has been ringfenced for developing (a) the NHS Test and Trace and (b) other database systems.

No assessment or decisions have yet been made on the use of NHS Test and Trace data systems for other purposes beyond those related to COVID-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, what assessment he has made of the (a) financial viability of the community pharmacy network in England and (b) adequacy of the interim covid-19 support package provided to that network; and if he will make a statement.

The Community Pharmacy Contractual Framework five-year deal, agreed in 2019 with the Pharmaceutical Services Negotiating Committee (PSNC), commits £2.592 billion annually to the sector. Maintaining access to pharmaceutical services is a priority for the Government and the Department continues to closely monitor the market. Discussions are ongoing with the PSNC about additional funding for costs incurred during the pandemic. As part of its ongoing assessment of COVID-19 costs incurred by the sector, the Government will take account of the £370 million increased advance payments paid to community pharmacies


The COVID-19 support package for community pharmacy also included general COVID-19 business financial support, funding for Bank Holiday openings, social distancing measures, the medicine delivery service to shielded patients and free personal protective equipment; as well as non-monetary support, including the removal of some administrative tasks, flexibility in opening hours and the delayed introduction of new services.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, whether he plans to use a development of the NHS Test and Trace database system to improve public services beyond what is necessary to tackle the covid-19 outbreak.

No assessment or decisions have yet been made on the use of NHS Test and Trace data systems for other purposes beyond those related to COVID-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, whether he plans to close the NHS Test and Trace database system once the covid-19 pandemic has ended.

No assessment or decisions have yet been made on the use of NHS Test and Trace data systems for other purposes beyond those related to COVID-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of using the information held in the NHS Test and Trace database system for other purposes.

No assessment or decisions have yet been made on the use of NHS Test and Trace data systems for other purposes beyond those related to COVID-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, whether he plans to close the NHS Test and Trace database system once the covid-19 outbreak in the UK has ended.

No assessment or decisions have yet been made on the use of NHS Test and Trace data systems for other purposes beyond those related to COVID-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the covid-19 outbreak and associated lockdown restrictions on cancer survival rates.

Local systems, drawing on advice and analysis from their Cancer Alliance, will ensure that there is sufficient diagnostic and treatment capacity in place to meet the needs of cancer to return the number of people waiting for longer than 62 days to the level of February 2020, or to the national average in February 2020 where this is lower, and meet the increased level of referrals and treatment required to address the shortfall in number of first treatments by March 2022.

No assessment has yet been made of the effect of COVID-19 on cancer survival rates because data to assess the full extent of its impact on patient outcomes is not yet available. The NHS Cancer Programme is currently establishing a task and finish group to review alterations and/or disruptions to care pathways. Once this group has been established a timeline will be agreed and they will consider the most appropriate data sources with which to make this assessment.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the length of time it will take to clear the cancer treatment backlog.

Local systems, drawing on advice and analysis from their Cancer Alliance, will ensure that there is sufficient diagnostic and treatment capacity in place to meet the needs of cancer to return the number of people waiting for longer than 62 days to the level of February 2020, or to the national average in February 2020 where this is lower, and meet the increased level of referrals and treatment required to address the shortfall in number of first treatments by March 2022.

No assessment has yet been made of the effect of COVID-19 on cancer survival rates because data to assess the full extent of its impact on patient outcomes is not yet available. The NHS Cancer Programme is currently establishing a task and finish group to review alterations and/or disruptions to care pathways. Once this group has been established a timeline will be agreed and they will consider the most appropriate data sources with which to make this assessment.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, what discussions he has had with Cabinet colleagues on future uses of the NHS Test and Trace database system.

No such discussions have taken place.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the World Health Organisation on the criteria for declaring the end of the covid-19 global pandemic.

There have been no recent discussions. Such considerations are for the Director-General of the World Health Organization, with the advice of independent technical experts and based on public health evidence and data.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, what criteria his Department plans to use to define the end of the covid-19 outbreak in the UK.

Over time, scientists expect COVID-19 to become endemic, meaning the virus will reach a stable and, it is hoped, manageable level. Scientists do not yet know how or when that transition will occur, so the Government has not determined criteria for the end of the pandemic. The Government will continue to be guided by the best available scientific advice and the latest data when responding to the virus.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, what the total budget is for NHS Test and Trace.

The NHS Test and Trace budget for 2020/21 is £22 billion and £15 billion in 2021/22, a total budget over two years of £37 billion.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, whether financial or other resources have been allocated to assessing potential futures uses of the NHS Test and Trace database system.

Spending plans for the £15 billion budget in 2021-22 are currently undergoing a detailed financial planning exercise and will be finalised in due course.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Apr 2021
To ask the Secretary of State for Health and Social Care, how much has been spent on NHS Test and Trace to date.

Actual audited expenditure will be published as part of the Department’s Annual Report and Accounts.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
24th Mar 2021
To ask the Secretary of State for Health and Social Care, what steps the Government is taking to accelerate the (a) adoption and (b) uptake of vaccines approved by the Medicines Healthcare Products Regulatory Agency.

The vaccines approved for adoption in the United Kingdom have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare products Regulatory Agency (MHRA). The Joint Committee on Vaccination and Immunisation regularly reviews MHRA approved vaccines and makes recommendations to the Department. These recommendations are considered thoroughly before putting in place new vaccines. Any vaccine that is approved must go through the same clinical trials and safety checks as other licensed medicines.

A range of actions have been implemented to improve vaccination uptake for children of all ages in England. This includes initiatives to improve access to the immunisation programme; communication with the public; data to better identify underserved individuals and populations; and training for healthcare professionals.

Nadine Dorries
Secretary of State for Digital, Culture, Media and Sport
24th Mar 2021
To ask the Secretary of State for Health and Social Care, what steps the Government is taking to alleviate the effect of infant respiratory syncytial virus on (a) the NHS and (b) population health.

To alleviate the effect of respiratory syncytial virus (RSV) on the National Health Service, Public Health England (PHE) is working with NHS England as part of its preparing and planning for the 2021 RSV season. This includes ensuring access to Synagis out of season in the event of a spring/summer outbreak and ensuring that clinicians have access to the most up to date and evidence-based guidance to support patient treatment and safe discharge from hospital. PHE monitors levels of RSV activity in the population of England and Wales and publishes information throughout the RSV season.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
24th Mar 2021
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the long-term effect of infant respiratory syncytial virus on healthcare utilisation.

No such assessment has been made.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
24th Mar 2021
To ask the Secretary of State for Health and Social Care, whether covid-19 vaccines are eligible for the Medicines Healthcare Products Regulatory Agency’s Innovative Licensing and Access Pathway.

In principle, COVID-19 vaccines are eligible for applying to the Innovative Licensing and Access Pathway (ILAP). Inclusion in the ILAP is subject to fulfilment of the Innovation Passport criteria.

Nadine Dorries
Secretary of State for Digital, Culture, Media and Sport
9th Feb 2021
To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) support access to medicines in therapeutic areas where there is a lack of recent innovation and the unmet need is high and (b) ensure new treatments are not penalised as a result of being compared to a low cost standard of care.

We reformed the Cancer Drugs Fund (CDF) in 2016 to improve patient access to promising and innovative new cancer treatments.

The National Institute for Health and Care Excellence (NICE) appraises all new cancer drugs and is now able to recommend cancer drugs for use through the CDF where there is too much uncertainty to be able to recommend them for routine commissioning. Thousands of National Health Service patients in England have benefitted from rapid access to new cancer drugs as a result of the CDF and NICE recommended 92% of the cancer drugs it appraised in 2020.

NICE recognises its procedures need to keep pace with developments in medical innovation and is currently undertaking a review of its methods and processes. The methods review explores issues relevant to the appraisal of new cancer drugs, such as addressing uncertainty and taking account of innovation. However, it is too soon to comment on the potential outcomes and any changes to NICE’s methods that may be implemented.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
9th Feb 2021
To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) encourage medical innovation in blood cancers and (b) ensure access to newer targeted treatments are not restricted as a result of being compared to more toxic, low cost, chemotherapy alternatives.

We reformed the Cancer Drugs Fund (CDF) in 2016 to improve patient access to promising and innovative new cancer treatments.

The National Institute for Health and Care Excellence (NICE) appraises all new cancer drugs and is now able to recommend cancer drugs for use through the CDF where there is too much uncertainty to be able to recommend them for routine commissioning. Thousands of National Health Service patients in England have benefitted from rapid access to new cancer drugs as a result of the CDF and NICE recommended 92% of the cancer drugs it appraised in 2020.

NICE recognises its procedures need to keep pace with developments in medical innovation and is currently undertaking a review of its methods and processes. The methods review explores issues relevant to the appraisal of new cancer drugs, such as addressing uncertainty and taking account of innovation. However, it is too soon to comment on the potential outcomes and any changes to NICE’s methods that may be implemented.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
9th Feb 2021
To ask the Secretary of State for Health and Social Care, with reference to the recommendations made by the Decision Support Unit in its 2014 Report, Assessing technologies that are not cost-effective at zero price, what steps he is taking to support access to innovative medicines in response to those recommendations.

We reformed the Cancer Drugs Fund (CDF) in 2016 to improve patient access to promising and innovative new cancer treatments.

The National Institute for Health and Care Excellence (NICE) appraises all new cancer drugs and is now able to recommend cancer drugs for use through the CDF where there is too much uncertainty to be able to recommend them for routine commissioning. Thousands of National Health Service patients in England have benefitted from rapid access to new cancer drugs as a result of the CDF and NICE recommended 92% of the cancer drugs it appraised in 2020.

NICE recognises its procedures need to keep pace with developments in medical innovation and is currently undertaking a review of its methods and processes. The methods review explores issues relevant to the appraisal of new cancer drugs, such as addressing uncertainty and taking account of innovation. However, it is too soon to comment on the potential outcomes and any changes to NICE’s methods that may be implemented.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
26th Jan 2021
To ask the Secretary of State for Health and Social Care, what plans NHS England has to fund cancer molecular diagnostic tests centrally under the National Tariff Payment System in 2021-22.

The 2020/21 National Tariff:

“In addition, from 2020/21, all cancer genetic tests are now reimbursed outside of national prices. The existing funding arrangements will continue for diagnostic tests which have been excluded from tariff since 2015. These tests are: NRAS/KRAS testing, BRAF testing, KIT testing, ALK testing (1), ALK testing (2), Oncotype DX, PD-L1, Prosigna and EnoPredict.”

To support this £77.8 million was removed from the tariff. This is from the amount for National Prices and that was supplied to NHS England’s specialised commissioning.

These arrangements are proposed to continue and will be part of NHS England and NHS Improvement’s consultation on the contents of the 2021/22 National Tariff. The consultation is due imminently.

Edward Argar
Minister of State (Department of Health and Social Care)
26th Jan 2021
To ask the Secretary of State for Health and Social Care, what the timescale is for NHS England to consult on the national service specification for clinical genomics.

NHS England and NHS Improvement are currently progressing the updating of the Clinical Genomics Service Specification.

Stakeholder testing on the Clinical Genomics Service Specification will be undertaken in line with the NHS England and NHS Improvement policy and is expected to take place in early 2021.

Edward Argar
Minister of State (Department of Health and Social Care)
26th Jan 2021
To ask the Secretary of State for Health and Social Care, how many NHS cancer patients in England received a fusion gene mutation test for (a) ALK, (b) NTRK, (c) RET, and (d) ROS1 in 2020.

NHS England and NHS Improvement currently do not hold this data.

Edward Argar
Minister of State (Department of Health and Social Care)
26th Jan 2021
To ask the Secretary of State for Health and Social Care, what the timescale is for NHS England to expand access to routine genomic profiling for eligible cancer patients with metastatic/locally-advanced disease.

In the NHS Long Term Plan, NHS England and NHS Improvement outlined the commitment to offer more extensive genomic testing to patients who are newly diagnosed with cancers so that by 2023 over 100,000 people a year can access these tests.

A range of genomic testing for patients with cancer covering both adult and paediatric solid and haematological cancers is already available through the NHS Genomic Medicine Service as outlined in the National Genomic Test Directory.

Edward Argar
Minister of State (Department of Health and Social Care)
8th Dec 2020
To ask the Secretary of State for Health and Social Care, what plans he has in place to expand the scope of the MedTech Funding Mandate to cover new products not previously included in the (a) Innovation and Technology Tariff and (b) Innovation and Technology Payment programmes.

At the current time, there are no plans to expand the scope of the MedTech Funding Mandate. To identify medical devices, diagnostics and digital products which are likely to meet the MedTech Funding Mandate criteria, NHSX will regularly review the National Institute for Health and Care Excellence’s guidance and recommendations. The launch of the fund has been delayed until at least April 2021 due to the suspension of the 2020/21 NHS Standard Contract and the 2020/21 National Tariff Payment System during COVID-19.

Nadine Dorries
Secretary of State for Digital, Culture, Media and Sport
8th Dec 2020
To ask the Secretary of State for Health and Social Care, what plans he has to ensure equitable patient access to proven remote diagnostics to support home testing.

The Department and the National Health Service are prioritising the improvement of connectivity and digitisation across all aspects of diagnostics in order to drive efficiency, deliver seamless care across traditional boundaries and facilitate remote reporting.

The first four phases of the Artificial Intelligence in Health and Care award included innovations in remote diagnostics, including the Neuronostics Limited smartphone-based app which can receive electroencephalogram recordings from wireless headsets to assist with assessing epilepsy treatment; Senti Tech Limited’s project enabling remote chest examination for respiratory patients through sensors embedded into a jacket; and Healthy.io UK Limited’s smartphone albuminuria self-test, which uses a home test kit and a mobile app to allow patients to self-test at home with clinical grade results.

NHSX is supporting the COVID Oximetry @home services which remotely monitor the oxygen saturation levels of patients with COVID-19 symptoms. This offers both technology-enabled and standard services with paper diary and telephone check-in for those without smartphones. In some areas, devices are provided for people to use in their own homes. NHSX are also supporting the scaling of remote monitoring approaches across the seven regions in England. This includes a focus on vulnerable groups such as those living in care homes.

Nadine Dorries
Secretary of State for Digital, Culture, Media and Sport
8th Dec 2020
To ask the Secretary of State for Health and Social Care, what plans Public Health England has to update its guidance on the diagnosis of urinary tract infections to reflect changes in remote diagnostic techniques.

The current Public Health England (PHE) diagnostic urinary tract infection guidance features a diagnostic flowchart for over 65 year olds, which can be followed during remote consultation such as telephone or video consultations and does not recommend urine dipsticks.

The flowchart for under 65 year olds encourages diagnosis based on three symptoms that can be assessed remotely. Current guidance advises that patients with only one of these are tested using a urine dipstick, this could be facilitated by patients providing a urine sample from home for testing.

The guidance advises that clinicians should consider in patients with milder symptoms a back-up antibiotic prescription with appropriate pain relief. This would reduce the need for patients to attend the surgery. This guidance was last updated in October 2020 and will be reviewed again in November 2021. The recently updated guidance is available at the following link:

https://www.gov.uk/government/publications/urinary-tract-infection-diagnosis

PHE is collaborating with the Royal College of General Practitioners to develop training materials on antibiotic prescribing in remote consultations.

Edward Argar
Minister of State (Department of Health and Social Care)
10th Nov 2020
To ask the hon. Member for South West Bedfordshire, representing the Church Commissioners, what assessment the Commissioners have made of (a) trends in the level of closure of churches and (b) the ability of worshipping communities to fund ongoing repairs to church buildings.

The details of individual parish finances is not generally a matter for the Church Commissioners, though other parts of the National Church Institutions and dioceses have been keeping planned giving and donations under careful review. Churches that have a solid foundation of regular giving through direct debit or standing order appear to be withstanding the pandemic much better than those whose finances were more reliant on church hall income, fundraising events, visitor donations and cash in the offertory plate. During the first national lockdown whilst some parishes saw a substantial drop off in donations others have embraced new technology using digital giving, and social media and, when Church buildings are open, contactless giving.

Although there has been a significant reduction in parish payments to dioceses to fund ministry costs, this has been less than anticipated at the start of the national lockdown, in part boosted by use of reserves as well as the generosity of givers. We grateful to the Government for allocating over £30million from the Culture Recovery Fund to support major churches and cathedrals. The Church Commissioners have also made significant funds available where possible to support music, essential craft and tradespeople alongside sustainability funding and salary support for cathedrals. The continuation of the Listed Places of Worship Grant Scheme is also important for the future funding of repairs to church buildings and the Archbishops’ Council have made representations to the Treasury about this.

Andrew Selous
Second Church Estates Commissioner
21st Oct 2020
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve early accurate diagnosis for rare diseases.

The Government recognises the importance of patients across all areas of the United Kingdom being able to obtain a quick and accurate diagnosis.

The 2013 UK Rare Disease Strategy has helped to increase awareness amongst healthcare professionals to refer patients into specialist services. Earlier detection of rare diseases is benefitting from advances in genomics and the commitment to incorporate whole genome sequencing into routine healthcare by the NHS Genomic Medicine Service. The recently published Genome UK Strategy outlines the Government’s vision to help people live longer, healthier lives using new genomic technologies to diagnose and treat rare diseases. Additionally, the government plans to publish a new UK Rare Diseases Framework by the end of 2020 which will replace the UK Rare Diseases Strategy.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
21st Oct 2020
To ask the Secretary of State for Health and Social Care, what assessment he has made of the ability of patients with rare to diseases to access specialist care and treatment during the covid-19 outbreak.

The Department, alongside NHS England, is considering the impact of COVID-19 on patients with rare diseases. NHS England has had discussions with some services and patients/patient groups to understand the impact of COVID-19 including what has worked well; what hasn’t worked so well; and opportunities for transformation.

NHS England will continue to look at what services can be delivered successfully through virtual communication technology such as telephone consultation and videoconferences. Where services do need to be delivered face-to-face, NHS England will work with providers to ensure that patients have a safe journey through the hospital to the treatment area.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
21st Oct 2020
To ask the Secretary of State for Health and Social Care, whether he plans to introduce an innovative medicines fund.

We made a commitment to extend the successful Cancer Drugs Fund into a new Innovative Medicines Fund to fund the most advanced, life-saving treatments for conditions such as cancer or autoimmune disease and for children with other rare diseases.

Proposals for the fund are in development and we expect NHS England and NHS Improvement and the National Institute for Health and Care Excellence to lead an engagement exercise early next year.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
21st Oct 2020
To ask the Secretary of State for Health and Social Care, when his Department will publish the criteria for determining orphan designation for medicines after the transition period; and whether he plans to consult with (a) patient groups, (b) industry and (c) other relevant stakeholders to help inform this criterion.

The Medicines and Healthcare products Regulatory Agency (MHRA) published guidance on 1 October 2020 on how orphan designation for medicines will be managed after the transition period on our website.

The Department and MHRA have held a series of engagement sessions which were open to all our stakeholders to inform on how medicines will be regulated including such medicines after the end of the transition period.

Nadine Dorries
Secretary of State for Digital, Culture, Media and Sport
20th Oct 2020
To ask the Secretary of State for Health and Social Care, what proportion of covid-19 tests returned a positive result, in each month since January 2020, by English county.

We publish data on daily pillar 2 tests processed by lower tier local authority and sperate weekly demographic information on people tested and people testing positive for COVID-19 across pillars 1 and 2 throughout England each week alongside other Test and Trace statistics. This data is available at the following link:

https://www.gov.uk/government/collections/nhs-test-and-trace-statistics-england-weekly-reports

Helen Whately
Exchequer Secretary (HM Treasury)
20th Oct 2020
To ask the Secretary of State for Health and Social Care, how many covid-19 tests have been carried out in each month since January 2020, by English county.

Weekly data for pillar 2 coronavirus testing is available for every lower tier local authority in England at the following link:

https://www.gov.uk/government/collections/nhs-test-and-trace-statistics-england-weekly-reports

Helen Whately
Exchequer Secretary (HM Treasury)
14th Oct 2020
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to mitigate the effect of the covid-19 outbreak on the (a) diagnosis and treatment of and (b) support available for patients with heart valve disease.

Primary and secondary care have remained open throughout the pandemic and patients have been encouraged to access these services.

Since 29 April NHS England has prioritised the reintroduction of non COVID-19 services with the aim of recovering as much performance as possible before winter. To aid this, new COVID-19 secure hubs for surgery and diagnostics have been established.

Further planning is underway to ensure critical services, such as cardiac surgery, are maintained during any future waves.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Oct 2020
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of the covid-19 outbreak on detection rates of (a) cardiovascular disease and (b) heart valve disease.

Detection rates are captured by general practitioner practices as part of the Quality and Outcomes Framework. This data is published yearly. Data is not yet available beyond 31 March 2020, which would show the impact of COVID-19 on detection rates.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
14th Oct 2020
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the early detection of heart valve disease within primary care and the wider community during the covid-19 outbreak.

Primary care and general practitioner practices have remained open throughout the pandemic and the National Health Service has prioritised treatment of the most urgent cases, including heart diseases. To continue to provide consultations in a COVID-19-safe environment, many practices are providing video or phone consultations. The NHS is prioritising restoration of the most urgently needed services, including diagnosis and treatment for patients with heart failure and heart valve disease.

In line with the diagnostics review ‘Diagnostics: Recovery and Renewal’, published on the 1 October, community diagnostic hubs are being established which will support with diagnostics, to improve the capacity to increase the detection of conditions such as cardiovascular disease and heart valve disease.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
12th Oct 2020
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect on people's health in Bolton local authority area of the reduction in GP referrals of almost 20,000 as a result of the covid-19 lockdown.

No specific assessment has been made.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
12th Oct 2020
To ask the Secretary of State for Health and Social Care, what assessment he has made of the health impact of missed GP appointments as a result of covid-19; and if he will make a statement.

General practice is open and people should continue to access services by phone, online or in person.

Although general practitioner appointment numbers fell in the early stages of lockdown, practices remained open offering more remote consultations to see as many patients as possible while protecting staff and patients from avoidable risk of infection. Appointment numbers are recovering and are returning to levels seen before lockdown.

Practices continue to undertake routine and preventative work including vaccinations and immunisations and screening, as well as supporting their more high-risk patients with ongoing care needs. Although it is still too early to carry out a full assessment of the impact, we continue to monitor the situation closely.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
12th Oct 2020
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of GP appointments that have been missed in the UK as a result of covid-19.

Data on the number of general practitioner appointments missed in the United Kingdom as a result of COVID-19 is not held.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
25th Sep 2020
To ask the Secretary of State for Health and Social Care, for what reasons the Spring publication by NHS England of its MedTech Funding Mandate has not yet been published; and what the timescale is for issuing that publication.

I refer the hon. Member to the answer to Question 52079 on 10 June 2020.

Edward Argar
Minister of State (Department of Health and Social Care)
16th Sep 2020
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of (a) false positive and (b) false negative results from PCR testing for covid-19 since the beginning of the covid-19 outbreak.

The information is not held in the format requested.

Helen Whately
Exchequer Secretary (HM Treasury)
1st Sep 2020
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on the lessons that can be learned from its agility during the covid-19 outbreak in order to enable the rapid review of paused appraisals now that that activity has resumed; and what additional support he plans to provide to reduce further delays to patients in accessing new and innovative treatments.

Departmental Ministers and officials regularly discuss a range of matters with colleagues in the National Institute for Health and Care Excellence (NICE).

NICE is using the lessons learned from developing rapid guidelines in response to COVID-19 to review how it produces and presents guidance, while maintaining its commitment to providing robust, evidence-based and independent advice. NICE remains committed to publishing final guidance for new medicines within 90 days of licensing.

NICE is also working with NHS England and NHS Improvement on the development of an Innovative Medicines Fund so that doctors can use the most advanced, life-saving treatments for conditions such as cancer or autoimmune disease, or for children with other rare diseases. NICE and NHS England and NHS Improvement plan to consult on the proposals toward the end of this year.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
17th Jul 2020
To ask the Secretary of State for Health and Social Care, what progress he has made in providing genomic testing for cancer patients who could benefit from treatment with histology independent therapies.

The first candidate histology independent therapy, larotrectinib, for treating advanced solid tumours with NTRK gene fusions has been approved by the National Institute for Health and Care Excellence (NICE) through the Cancer Drugs Fund, and final appraisal documentation was published by NICE on 21 April 2020. In line with the publication of the final appraisal documentation, NHS England and NHS Improvement put in place genomic testing for NTRK gene fusions, delivered by the NHS Genomics Laboratory Hubs (GLHs). NHS England and NHS Improvement is continuing to work with the GLHs to ramp up the capacity of NTRK gene fusion testing.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
16th Jul 2020
To ask the Secretary of State for Health and Social Care, what his timescale is for updating the National Genomic Test Directory for 2020-21 for genomic tests commissioned by the NHS in England for cancer.

Due to the impact of COVID-19, the publication of the National Genomic Test Directory for 2020/21 has been delayed. NHS England and NHS Improvement are establishing the timescale for the publication of the updated National Genomic Test Directory for 2020/21 in line with national COVID-19 recovery activity. It is expected that the National Genomic Test Directory for 2020/21 will be published by the end of September.

Helen Whately
Exchequer Secretary (HM Treasury)
16th Jul 2020
To ask the Secretary of State for Health and Social Care, what progress has been made in the development and implementation of pan-cancer testing panels as part of the NHS Genomic Medicine Service.

There are seven Genomic Laboratory Hubs across England which are each responsible for coordinating services for a particular part of the country, and together they form the national Genomic Medicine Service. Each Genomic Laboratory Hub has developed an implementation plan and are continuing to develop pan-cancer panels for implementation as part of the NHS Genomic Medicine Service. NHS England and NHS Improvement continue to monitor progress on the development and implementation of pan-cancer panels.

Helen Whately
Exchequer Secretary (HM Treasury)
16th Jul 2020
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the covid-19 outbreak on genomic testing capacity for cancer within the NHS Genomic Laboratory Hubs network.

NHS England and NHS Improvement closely monitored the effect on genomic testing services of COVID-19, including the impact of the redeployment of equipment and staff to support COVID-19 testing. In order to ensure continuity of the genomic testing services, NHS England and NHS Improvement published prioritisation guidance at the following link:

https://www.england.nhs.uk/coronavirus/publication/guidance-to-the-nhs-genomic-medicine-service-in-response-to-covid-19/

NHS England and NHS Improvement continue to work closely with the Genomic Laboratory Hubs to monitor any impacts on testing capacity.

Helen Whately
Exchequer Secretary (HM Treasury)
13th Jul 2020
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 June 2020 to Question 52076 on Diabetes: Medical Treatments, if he will make it his policy to ensure transparency in prescribing data in formularies in both (a) community pharmacies and (b) other settings.

The Government is committed to transparency in prescribing data and there are a variety of processes used to monitor prescribing patterns and variation in the prescribing of technologies in both prescribing in the community and hospital settings for people with diabetes.

The NHS Business Services Authority operates an Open Data Portal on their website which is available for public use to enable interested stakeholders to access prescribing data. Information is also publicly available at the following link:

https://www.nhsbsa.nhs.uk/open-data-portal-odp

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
6th Jul 2020
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the effect of the covid-19 outbreak on (a) reforms to funding mechanisms and (b) other plans for community pharmacies set out in the five-year Community Pharmacy Contractual Framework.

Under the Community Pharmacy Contractual Framework (CPCF), £2.592 billion a year was committed to the community pharmacy sector in the five-year deal from 2019/20 to 2023/24 for the National Health Service pharmaceutical services they provide, a total of nearly £13 billion. To maintain access in areas where there are fewer pharmacies or higher health needs, additional payments, from within that funding, are made under the Pharmacy Access Scheme to eligible pharmacies.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
6th Jul 2020
To ask the Secretary of State for Health and Social Care, what assessment his Department has made on the role of distance-selling pharmacies in ensuring patient access to repeat prescriptions is not disrupted during and after the covid-19 pandemic, including when the shielding programme ends.

The Department has made no such assessment. All pharmacies, including distance-selling pharmacies have a duty to patients to dispense prescriptions promptly regardless of whether they are part of the shielded population.

NHS England and NHS Improvement are encouraging general practitioners to issue patients with prescriptions via electronic Repeat Dispensing (eRD), where clinically appropriate, to facilitate easier patient access to their repeat prescriptions

NHS England and NHS Improvement commissioned a Medicine Delivery Service from both community pharmacies and dispensing doctors to ensure delivery of medicines to shielded patients during the duration of the programme which comes to an end on 31 July. NHS Volunteer Responders will continue to be available to support people including with medication delivery, beyond 31 July.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
18th Jun 2020
To ask the Secretary of State for Health and Social Care, what criteria his Department will use to prioritise the backlog of outstanding applications created by the suspension of Part IX of the NHS England and Wales Drug Tariff.

Applications to Part IX of the Drug Tariff will be reviewed in receipt order, with the earliest applications reviewed first, when the process resumes.

If an application is for a product that helps in the treatment of COVID-19 then it would be considered outside of the normal review process.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
18th Jun 2020
To ask the Secretary of State for Health and Social Care, when the assessment of new and pending applications to the NHS England and Wales Drug Tariff will resume.

The assessment of new and pending applications to the Drug Tariff has been suspended temporarily, to manage staff resource during the COVID-19 pandemic. A date for the resumption of the application assessment process has not yet been agreed.

This suspension is reviewed regularly to inform when the assessment process will resume.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
1st Jun 2020
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the levels of precautionary antibiotic prescribed in primary care during the covid1-19 outbreak; and what steps he is taking to manage the effect of those prescriptions on antimicrobial resistance.

Public Health England’s (PHE’s) English surveillance programme for antimicrobial utilisation and resistance (ESPAUR) is working with the National Health Service and across sectors, to develop and maintain surveillance systems for monitoring trends in antimicrobial use and resistance in England. Data can be viewed on the antimicrobial resistance Fingertips webpage at the following link:

https://fingertips.phe.org.uk/profile/amr-local-indicators

PHE will track the impact of COVID-19 on antimicrobial resistance and utilisation using these established surveillance data systems.

PHE has worked closely with the Royal College of General Practitioners to develop the Treat Antibiotics Responsibly Guidance Education Tools to encourage appropriate antibiotic use. E-learning modules have been developed which cover the management of COVID-19 and the importance of using antibiotics in line with prescribing guidance. The education tools can be viewed at the following link:

https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/amr/target-antibiotics-toolkit.aspx

PHE is continuously monitoring antimicrobial resistance trends for key organisms isolated from respiratory and blood specimens reported via national laboratory surveillance and will alert stakeholders of changes relevant to clinical therapy decisions and policy recommendations.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
1st Jun 2020
To ask the Secretary of State for Health and Social Care, what the Government's timeframe is for the (a) publication and (b) implementation of the MedTech Funding Mandate; and if he will make a statement.

Due to COVID-19 NHS England and NHS Improvement have delayed the publication of the MedTech Funding Mandate and will not be launching this during 2020/21.

To maintain patient access to innovative devices, diagnostics and digital products NHS England and NHS Improvement continue to fund a range of technologies through the Innovation and Technology Payment.

Nadine Dorries
Secretary of State for Digital, Culture, Media and Sport
1st Jun 2020
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the opportunities to provide other adult vaccinations alongside the flu programme to maximise every contact with a patient and decrease pressure on the NHS by avoiding multiple visits by vulnerable people.

The Department is working with colleagues at NHS England and NHS Improvement, and Public Health England on the delivery of the 2020/21 seasonal flu vaccination programme. The operational plans for flu include consideration of the requirements of vulnerable people, the workforce and providers, with respect to current social distancing measures, and the potential impact on other vaccination programmes. We continually assess opportunities to improve access to all vaccinations. This includes whether other adult vaccination can be delivered alongside flu vaccination where possible.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
1st Jun 2020
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to introduce specific plans after the covid-19 outbreak to encourage eligible patients through proactive measures, such as call and recall, to attend primary care to get the shingles vaccine.

People in the age group eligible for the shingles vaccine are required to take particular care to avoid situations where they are at higher risk of acquiring COVID-19 and are therefore not currently being actively called for immunisation by their general practitioner (GP). However, if they are attending the GP practice for other reasons and it is clinically appropriate to offer shingles vaccine, they will be given the vaccine.

Maintaining routine vaccination services during COVID-19 and recovering delivery of our national immunisation programme are high priorities for the Government and the health and care sector but need to be considered in light of social distancing and shielding measures. An immunisation recovery plan is being drawn up by NHS England and NHS Improvement, taking into account risk assessment advice from Public Health England, which will include proactive use of call/recall.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
1st Jun 2020
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase workforce capacity to support the school vaccination programme in 2020 and catch up vaccination programmes.

NHS England and NHS Improvement are working to restore school-age vaccination programmes that have paused due to school closures. This planning is based on local need and will include an assessment of the workforce capacity needed to restore these services, as well as consideration as to whether an increase to the current workforce is required.

The operational planning also includes working with schools to consider other steps to increase capacity, such as vaccinating during the school holidays, where necessary.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
1st Jun 2020
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of providers outside of primary care providing immunisation services and support catch-ups with patients to relieve pressure on primary care.

Providers other than primary care make a valuable contribution to the national immunisation programmes, for example, some maternity services provide pertussis and flu vaccinations, and most school-aged vaccinations take place outside of primary care.

The 2019 National Health Service review of vaccinations and immunisations delivery sought to explore how to increase uptake of vaccinations and consider if vaccines could be safely and efficiently delivered by providers other than general practice, building on the contribution of community pharmacies to seasonal influenza coverage, and the possibility to widen the range of health professionals who deliver vaccinations.

Any changes in delivery models would be carefully considered with due regard to patient safety, data flows, impact on outcomes and contractual requirements.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
1st Jun 2020
To ask the Secretary of State for Health and Social Care, what plans are in place to ensure lessons learned during the covid-19 pandemic including the use of proven apps and digital solutions, are embedded into relevant patient pathways for long term conditions.

During the pandemic, digital and remote general practitioner consultations and outpatient appointments have become usual across England. Providers have been rolling out remote consultations using video, telephone, email and text message services as a priority. David Probert, chief executive of Moorfields Eye Hospital NHS Foundation Trust, has been leading a taskforce to support acute providers to rapidly create these capabilities, with NHSX leading on primary care. As the National Health Service moves to return to business as usual activity, services across the country will look to maintain and build on new ways of working that have demonstrated their effectiveness during the pandemic.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
1st Jun 2020
To ask the Secretary of State for Health and Social Care, what processes are in place to monitor variation in the prescribing of technologies for people with diabetes in formularies throughout England.

There are a variety of processes used to monitor prescribing patterns and variation in the prescribing of technologies for people with diabetes. These are based on community pharmacy reimbursement data and include tools such as Open Prescribing, which is publicly available on the NHS Business Services Authority’s ePACT2 platform and PrescQIPP.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
4th May 2020
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure that Public Health England recommendations are being implemented for (a) people working in close contact with people who are at high-risk of chickenpox and (b) NHS staff without a confirmed history of chickenpox during the covid-19 outbreak.

In most cases chickenpox (varicella-zoster) is a self-limiting condition which can be safely managed at home. Post-exposure management using varicella-zoster immunoglobulin is used to protect individuals at high risk of suffering from severe chickenpox.

The ‘Green Book’1 guidance is based on advice from Public Health England, the Joint Committee on Vaccination and Immunisation and the standards expected of health and care professionals by their regulatory bodies. It is the responsibility of all health and care professionals to keep themselves informed of any developments which may have a bearing on their area of practice. Current personal protective equipment and social distancing COVID-19 guidance also applies.

Note:

[1] https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book#the-green-book

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
1st May 2020
To ask the Secretary of State for Health and Social Care, for what reason chickenpox is not a notifiable disease in England.

In England, notifiable diseases are outlined under the Health Protection (Notification) Regulations 2010.

When the regulation was created, the addition of chickenpox was considered, however, it was not included. This is because a provision is in place requiring notification of any infectious diseases which may pose a significant risk to human health. This was deemed to cover exceptional cases where public health action would be needed.

The Department keeps the diseases which are notifiable in England under review.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
1st May 2020
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the reasons for the increase in the number of hospital admissions of people with chickenpox; and whether he has made an assessment of the correlation between the rate of cases of chickenpox and hospital admissions.

Public Health England has not assessed the correlation between the rates of cases of chickenpox and hospital admissions. However, in 2019, Eurosurveillance published a study of hospitalisation due to varicella in England between 2004 and 2017.

The study showed there were 61,024 admissions with varicella between 2004 and 2017 and 38.1% had a recognised varicella complication. Hospitalisation increased by 25% and the proportion with complicated varicella increased by 24% from 2004/05 to 2016/17. The most common complications were bacterial skin infections, pneumonia, febrile convulsions and encephalitis.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
1st May 2020
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential effect of social distancing measures put in place due to the covid-19 outbreak on the future incidence and outcomes of vaccine preventable diseases which (a) are included and (b) not included in the UK National Immunisation Programme.

Public Health England (PHE) and NHS England and NHS Improvement are working with regional commissioners to ensure that routine immunisations continue to be delivered in primary care settings to ensure those eligible are protected against a range of vaccine preventable diseases. General practices continue to offer routine vaccination services, using social distancing and personal protective equipment according to national guidelines. Programmes delivered through schools are currently on hold and will be rescheduled as schools open.

PHE continues to promote the importance of routine immunisations particularly for children and those in clinical risk groups, for example through the Vaccine Update at the following link:

https://www.gov.uk/government/collections/vaccine-update

Preliminary data indicates there has not been a significant reduction in the number of primary immunisation doses administered compared to the previous year, though there is some indication of a decrease in the first dose of measles, mumps and rubella vaccinations. These data can be viewed at the following link:

https://www.medrxiv.org/content/10.1101/2020.05.07.20094557v1

The Government’s COVID-19 Action Plan has stated that everyone should ensure that they and their family’s vaccinations are up-to-date, as this will help to reduce any pressure on the National Health Service from vaccine-preventable diseases. Further information is available at the following link:

https://www.gov.uk/government/publications/coronavirus-action-plan/coronavirus-action-plan-a-guide-to-what-you-can-expect-across-the-uk

Immunisations outside of the UK National Immunisation Programme, such as those for travel and occupational health purposes, are unlikely to have a significant effect on public health due to these being primarily individual risks not population level risks.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
23rd Mar 2020
To ask the Secretary of State for Health and Social Care, what assessment he has made of the role of Dispensing Appliance Contractors in the provision of key (a) products and (b) services to the NHS during the covid-19 pandemic; and what support his Department plans to provide intends to provide to ensure the provision of those contractors' services.

There are no known supply issues linked to COVID-19 for appliances routinely dispensed by Dispensing Appliance Contractors like wound dressings, stoma and incontinence appliances. We are working with the supply chain to ensure Dispensing Appliance Contractors can source these products and maintain supply to patients.

Dispensing Appliance Contractors like any other primary care providers should follow Public Health England’s guidance on COVID-19.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
23rd Mar 2020
To ask the Secretary of State for Health and Social Care, what steps he has taken to help ensure that dispensing appliance contractors can deliver essential medical supplies on the same terms as pharmacists during the covid-19 outbreak.

Dispensing Appliance Contractors as part of their essential services have always been required to deliver certain appliances to patients’ homes and are reimbursed for doing so.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
23rd Mar 2020
To ask the Secretary of State for Health and Social Care, whether people working in (a) warehouse, (b) packing and (c) delivery services of manufacturers of medical devices supplied to the NHS are classified as key workers.

The Government has published guidance for key workers, specifically relating to schools, which can be found at the following link:

https://www.gov.uk/government/publications/coronavirus-covid-19-maintaining-educational-provision/guidance-for-schools-colleges-and-local-authorities-on-maintaining-educational-provision

The guidance states that ‘those working as part of the health and social care supply chain, including producers and distributers of medicines and medial and personal and protective equipment’ are classified as key workers.

Helen Whately
Exchequer Secretary (HM Treasury)
17th Mar 2020
To ask the Secretary of State for Health and Social Care, whether the GP contract 2020-21 supporting guidance will require all practices to implement a proactive call and recall for the shingles national immunisation programme to ensure the protection of older adults.

Immunisations play a critical role in preventative healthcare and in promoting health and well-being across the life course, particularly for older adults where protection against shingles is so important. The ‘Update to the GP contract agreement 2020/21 – 2023/24’ jointly published by NHS England and the British Medical Association on the 6th February 2020 states that practices should ensure their call and recall systems are in line with national standards. These will be defined in supporting guidance for each vaccination programme and over time will be updated to reflect use of the most effective technology. Some areas already use text-based reminders, and all practices must move towards this as soon as the infrastructure is in place. Call/recall will be delivered by practices themselves as a default or may be delivered by the local Child Health Information Systems (CHIS) on their behalf.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
16th Mar 2020
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the average cost to families of parents and carers taking time off work to care for children with chickenpox; and if he will make a statement.

The Joint Committee on Vaccination and Immunisation (JCVI), which provides the Government with expert advice on the provision of vaccination and immunisation services, does not routinely include non-health-related assessments such as these when considering evidence towards their recommendations.

Our chickenpox (varicella) immunisation programme, following advice from the JCVI, is targeted at those who are in close contact with people who are at high risk from chickenpox, such as siblings of a leukaemic child, or a child whose parent is undergoing chemotherapy. The JCVI does not currently recommend universal varicella vaccine as part of the routine childhood programme.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
16th Mar 2020
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that all medical device businesses are re-certified so that they comply with the Medical Device Regulation before the May 2020 deadline.

The new Medical Device Regulation (MDR), which will become United Kingdom law from 26 May 2020 as part of the European Union Withdrawal Act 2019, substantially strengthens the regulatory framework for medical devices and notified bodies and manufacturers are having to make significant changes to meet the enhanced requirements.

The Government recognises the importance of having competent notified bodies in place to ensure continuity of supply of products to the UK market. Therefore, the Medicines and Healthcare products Regulatory Agency (MHRA) has been engaging with UK industry and notified bodies on an ongoing basis to ensure that they are prepared for the implementation of the MDR.

There are also transitional provisions in place which enable existing CE marked devices to remain valid for sale until the date of expiry of that certificate. This means in practice that all devices on the UK market do not require immediate re-certification.

The MHRA will publish further guidance on how we intend to support businesses who may struggle to obtain certification under the MDR and to ensure continuity of supply of medical devices to UK patients.

Nadine Dorries
Secretary of State for Digital, Culture, Media and Sport
16th Mar 2020
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of working days that are lost each year as a result of parents caring for a child with chickenpox.

The Joint Committee on Vaccination and Immunisation (JCVI), which provides the Government with expert advice on the provision of vaccination and immunisation services, does not routinely include non-health-related assessments such as these when considering evidence towards their recommendations.

Our chickenpox (varicella) immunisation programme, following advice from the JCVI, is targeted at those who are in close contact with people who are at high risk from chickenpox, such as siblings of a leukaemic child, or a child whose parent is undergoing chemotherapy. The JCVI does not currently recommend universal varicella vaccine as part of the routine childhood programme.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
16th Mar 2020
To ask the Secretary of State for Health and Social Care, how many staff members within the Medicines and Healthcare products Regulatory Agency are reviewing re-certification applications to comply with the Medical Devices Regulation.

The new Medical Device Regulation (MDR), which will become United Kingdom law from 26 May 2020 as part of the European Union Withdrawal Act 2019, substantially strengthens the regulatory framework for medical devices and notified bodies and manufacturers are having to make significant changes to meet the enhanced requirements.

The Government recognises the importance of having competent notified bodies in place to ensure continuity of supply of products to the UK market. Therefore, the Medicines and Healthcare products Regulatory Agency (MHRA) has been engaging with UK industry and notified bodies on an ongoing basis to ensure that they are prepared for the implementation of the MDR.

There are also transitional provisions in place which enable existing CE marked devices to remain valid for sale until the date of expiry of that certificate. This means in practice that all devices on the UK market do not require immediate re-certification.

The MHRA will publish further guidance on how we intend to support businesses who may struggle to obtain certification under the MDR and to ensure continuity of supply of medical devices to UK patients.

Nadine Dorries
Secretary of State for Digital, Culture, Media and Sport
16th Mar 2020
To ask the Secretary of State for Health and Social Care, how many people have been (a) diagnosed with and (b) hospitalised as a result of chickenpox in (i) England and (ii) the UK in each of the last five years.

Chickenpox is not a notifiable disease in England, therefore data on the exact number of people diagnosed with chickenpox are not available.

A count of finished admission episodes with a primary diagnosis of chickenpox in England for the financial years 2014-15 to 2018-19, provided by NHS Digital, is attached.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
16th Mar 2020
To ask the Secretary of State for Health and Social Care, whether the Government's proposed vaccination strategy will include an approach to limiting the impact of chickenpox on society; and if he will make a statement.

The forthcoming vaccine strategy will consider all vaccination programmes over the life-course. The strategy does not directly consider the impact of chickenpox on society. However, it will build on efforts already under way to improve national immunisation programmes and support innovation.

Our chickenpox (varicella) immunisation programme, following advice from the Joint Committee on Vaccination and Immunisation (JCVI), is targeted at those who are in close contact with people who are at high risk from chickenpox, such as siblings of a leukaemic child, or a child whose parent is undergoing chemotherapy. The JCVI does not currently recommend universal varicella vaccine as part of the routine childhood programme.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
5th Mar 2020
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect on national health of the Childhood Vaccination Coverage Statistics for England 2018-19.

Public Health England (PHE) monitors trends in the level of childhood vaccination rates.

Although vaccination rates remain high, England has seen a small decline in coverage since 2013. The most recent figures, published in December 2019, show that vaccine coverage increased slightly compared to the last quarter for most routine vaccines measured at 12 months, representing vaccines administered recently. This increase in vaccination rates is for the second quarter in a row, and although it is always difficult to draw conclusions from small variations in the quarterly data, we look forward to this trend continuing in future reports.

This data can be viewed at the following link:

https://www.gov.uk/government/statistics/cover-of-vaccination-evaluated-rapidly-cover-programme-2019-to-2020-quarterly-data

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
5th Mar 2020
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effect of the availability of GP appointments on rates of vaccination in England.

Access to general practitioner (GP) appointments is key to good vaccination uptake and coverage. The NHS Long Term Plan published in January 2019 committed to improve access to primary care through a range of initiatives including more healthcare staff working in and with GP practices where many patients receive their vaccinations. As part of this work, there has been a national review of access to general practice services that commenced in July 2019 and will complete in 2020, which has already informed contract discussions for 2020/21. The results of these discussions were published in February 2020 as part of the updated GP contract deal for 2020/21 which can be found at the following link:

https://www.england.nhs.uk/gp/investment/gp-contract/

One of these actions relates to developing a nationally consistent extended access offer reflecting what works best in existing local schemes.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
4th Mar 2020
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the reinstatement of the UK's WHO measles-free status.

As a first step toward the World Health Organization reinstating the United Kingdom’s measles-free status, Public Health England (PHE) re-convened a multi-stakeholder measles and rubella elimination group, including NHS England, to develop a UK-wide strategy. The purpose of the strategy is to renew stakeholders’ commitment to elimination and re-focus efforts to ensure this will be sustained in the medium- and long-term. A multi-agency implementation board is taking forward the actions of the strategy working with key national and local stakeholders.

NHS England and General Practitioners Committee England also agreed the introduction of a new measles, mumps and rubella catch-up programme for 10 and 11-year olds who have not received a completed course of vaccines via the routine immunisation programme.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
4th Mar 2020
To ask the Secretary of State for Health and Social Care, what assessment he has made of trends in the number of mumps cases in England in each of the last five years.

Public Health England (PHE) has published annual data on the number of laboratory confirmed mumps cases from 1996 to 2019 at the following link:

https://www.gov.uk/government/publications/measles-confirmed-cases/confirmed-cases-of-measles-mumps-and-rubella-in-england-and-wales-2012-to-2013

Provisional PHE data show that there were 5,042 lab-confirmed cases of mumps in England in 2019, compared to 1,066 cases in 2018. This is the highest number of cases since 2009. The rise in cases looks set to continue in 2020, with over 1,000 confirmed cases in January 2020 compared to 191 during the same period in 2019. This can be viewed at the following link:

https://www.gov.uk/government/news/mumps-outbreaks-across-england

The steep rise in cases in 2019 has been largely driven by outbreaks in universities and colleges. Many of the cases in 2019 were seen in the so-called ‘Wakefield cohorts’ – young adults born in the late nineties and early 2000s who missed out on the measles, mumps and rubella vaccine when they were children. These cohorts are now old enough to attend college and university and are likely to continue fuelling mumps outbreaks into 2020.This can be viewed at the following link:

https://www.gov.uk/government/publications/mumps-confirmed-cases/mumps-confirmed-cases-in-england-and-wales-by-age-and-region-2012-to-2013

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
21st Jul 2021
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what recent assessment he has made of Hezbollah's potential involvement in the narcotics trade in South America.

Illegal drugs are a global threat. The UK works with partners around the world to coordinate action and combat organised crime groups operating across borders. The UK proscribes Hizballah in its entirety as a terrorist organisation and has an asset freeze in place against the entire organisation.

James Cleverly
Minister of State (Foreign, Commonwealth and Development Office)
19th Apr 2021
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what discussions he has had with Cabinet colleagues on future uses of the NHS Test and Trace database system.

No such discussions have taken place.

Wendy Morton
Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
19th Apr 2021
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, whether his Department plans to use the NHS Test and Trace database system.

No assessment has yet been made, nor any decisions made, on whether to use the data systems used by NHS Test and Trace for other purposes beyond those related to Covid-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Wendy Morton
Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
19th Apr 2021
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, whether he has allocated any financial or other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace database system.

No assessment has yet been made, nor any decisions made, on whether to use the data systems used by NHS Test and Trace for other purposes beyond those related to Covid-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Wendy Morton
Parliamentary Under-Secretary (Foreign, Commonwealth and Development Office)
5th Feb 2021
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what assessment he has made of the implications for his policies of confirmation by Iran's envoy to the International Atomic Energy Agency that Iran has two cascades of advanced centrifuges with almost four times the enrichment capacity of previous ones in operation at its underground Natanz facility.

Iran's continued systematic non-compliance with its nuclear commitments under the Joint Comprehensive Plan of Action (JCPoA) is jeopardising our efforts to preserve the JCPoA and risks compromising the important opportunity for a return to diplomacy with the new US Administration. We continue to engage closely with the US and JCPoA participants on this, and have made our position clear, including in recent E3 statements, that Iran must halt this activity, and return to compliance with its JCPoA commitments without delay.

James Cleverly
Minister of State (Foreign, Commonwealth and Development Office)
20th Jul 2020
To ask the Secretary of State for Foreign and Commonwealth Affairs, whether (a) Iran's Islamic Revolutionary Guards Corps and (b) other groups subject to UK terrorism and terrorist financing sanctions will be targeted under the Global Human Rights Sanctions Regulations 2020.

The UK is committed to holding Iran to account on a wide range of human rights issues. The Islamic Revolutionary Guard Corps is already sanctioned by the UK, as are a further 82 serious human rights violators and one entity, as an important part in keeping pressure on the Iranian regime to change its approach.

It is not appropriate to speculate on who may be designated under the Global Human Rights sanctions regime in the future. To do this could reduce the impact of the designations. We will keep all evidence and potential listings under close review.

James Cleverly
Minister of State (Foreign, Commonwealth and Development Office)
8th Jun 2021
To ask the Chancellor of the Exchequer, what steps the Government is taking to amend the existing R&D tax credits scheme to expand qualifying criteria to encourage larger companies to invest in research and innovation.

At Budget 2021, the Chancellor announced a review of R&D tax reliefs, supported by the publication of a wide-ranging consultation on the nature of private-sector R&D investment in the UK, how that is supported or otherwise affected by the R&D tax reliefs, and where changes may be appropriate.

The consultation closed on 2 June and next steps will be set out in due course.

15th Apr 2021
To ask the Chancellor of the Exchequer, whether his Department plans to use the NHS Test and Trace database system.

Throughout the pandemic, covid secure Treasury offices have been operating in line with government workplace guidance including use of the NHS Test and Trace service where appropriate.

Kemi Badenoch
Minister for Equalities
15th Apr 2021
To ask the Chancellor of the Exchequer, what discussions he has had with Cabinet colleagues on using the NHS Test and Trace database system.

In line with the practice of successive administrations, details of ministerial discussions are not normally disclosed.

Kemi Badenoch
Minister for Equalities
15th Apr 2021
To ask the Chancellor of the Exchequer, whether he has allocated any financial or other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace database system.

We have provided the Department of Health and Social Care with £15bn for NHS Test and Trace this year and they have also established the new UK Health Security Agency (UKHSA) to lead on future pandemic preparedness. Any questions relating to plans for NHS Test and Trace or the new UKHSA should be directed to the Department for Health and Social Care.

Kemi Badenoch
Minister for Equalities
2nd Dec 2020
To ask the Chancellor of the Exchequer, what assessment he has made of the financial support required by bowling centres due to covid-19 lockdown restrictions.

The Government recognises the extreme disruption the actions to combat Covid-19 are having on sectors like the leisure and entertainment industry.

That is why the Government has put in place an economic package of support which will provide businesses and individuals with certainty over the Winter months, even as measures to prevent further spread of the virus change. This includes the Coronavirus Job Retention Scheme and government-backed loan schemes. The Treasury has further provided funding to local authorities, to support both open and closed businesses through the Local Restrictions Support Grants and the Additional Restrictions Grant.

During this difficult time the Treasury is working intensively with employers, delivery partners, government departments like the Department for Digital, Culture, Media and Sport, and industry groups such as the British Association of Leisure Parks, Piers and Attractions, in order to understand the long-term effects of Covid-19 across all key areas of the economy.

We will continue to take a flexible approach and keep all impacts and policies under review as we respond to this pandemic.

Kemi Badenoch
Minister for Equalities
3rd Sep 2021
To ask the Secretary of State for the Home Department, how many people were granted refugee status in each year since 2010 broken down by local authority allocation.

The Home Office publishes data on asylum applications in the ‘Immigration Statistics Quarterly Release’. Data on the number of the initial decisions made on asylum applications and the number of refugees resettled by local authority through one of the UK’s resettlement schemes are published in tables Asy_D02 and Res_D01 of the asylum and resettlement detailed datasets; breakdowns by year are available. Information on how to use the dataset can be found in the ‘Notes’ page of the workbook. The latest published statistics relate to data up to the end of June 2021.


Please note the Home Office does not publish local authority breakdowns on asylum applications as the asylum system operates on a national level. Additionally, when an individual is granted refugee status they are no longer required to inform the Home Office of their address and are free to move around the UK.

Additionally, the Home Office publishes further data on asylum and resettlement in the asylum and resettlement summary tables. The ‘contents’ sheet contains an overview of all available data on asylum and resettlement.

Information on future Home Office statistical release dates can be found in the ‘Research and statistics calendar’.

Chris Philp
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
21st Jul 2021
To ask the Secretary of State for the Home Department, what recent assessment she has made of Hezbollah's potential involvement in the illegal drug trade in the UK.

Investigations into the activities of proscribed organisations are an operational matter for the police and intelligence agencies. It would not be appropriate to comment further.

Damian Hinds
Minister of State (Home Office) (Security)
19th Apr 2021
To ask the Secretary of State for the Home Department, whether she has allocated any financial or other resources from her Department's budget to investigate potential future uses by her Department of the NHS Test and Trace database system.

The Home Office has not allocated any financial or other resources for this purpose.

Kevin Foster
Parliamentary Under-Secretary (Home Office)
19th Apr 2021
To ask the Secretary of State for the Home Department, whether her Department plans to use the NHS Test and Trace database system.

The Home Office currently has no plans to use the NHS Test and Trace database system itself.

Kevin Foster
Parliamentary Under-Secretary (Home Office)
16th Apr 2021
To ask the Secretary of State for the Home Department, what discussions she has had with Cabinet colleagues on future uses of the NHS Test and Trace database system.

Use of the Test and Trace system is discussed periodically at cross departmental meetings as part of the Government’s response to the Covid-19 pandemic.

Kevin Foster
Parliamentary Under-Secretary (Home Office)
18th May 2021
To ask the Secretary of State for Defence, what steps his Department is taking to ensure that the armed forces are supported by world-class technological capabilities.

I refer the hon. Member to the answer I gave to the hon. Members for North Devon (Selaine Saxby), to Question 900383, and Newcastle Under-Lyme (Aaron Bell), to Question 900390, during Defence Oral Questions on 24 May 2021.

Jeremy Quin
Minister of State (Ministry of Defence)
1st Mar 2021
To ask the Secretary of State for Defence, pursuant to the Answer of 25 February 2021 to Question 156447 on International Criminal Court, what assessment he has made of the implications for UK military personnel of the International Criminal Court's decision of 5 February 2021; and if he will make a statement.

The UK respects the independence of the International Criminal Court (ICC), and we expect it to exercise due prosecutorial and judicial discipline. We continue to closely follow the ICC's work and are looking at the implications of this decision.

James Heappey
Parliamentary Under-Secretary (Ministry of Defence)
22nd Feb 2021
To ask the Secretary of State for Defence, if he will make an assessment of the implications for British military personnel of the International Criminal Court’s ruling that it has jurisdiction to open a probe into allegations of war crimes initiated by non-state actors.

We closely follow the work of the International Criminal Court and are looking at the implications of this decision.

James Heappey
Parliamentary Under-Secretary (Ministry of Defence)
22nd Feb 2021
To ask the Secretary of State for Defence, what discussions he has had with his International counterparts on the implications for military personnel of the ruling that non-state actors can initiate proceedings at the International Criminal Court (ICC), with reference to the February 2021 decision that the ICC has jurisdiction over the West Bank, Gaza and East Jerusalem.

We closely follow the work of the International Criminal Court and are looking at the implications of this decision.

James Heappey
Parliamentary Under-Secretary (Ministry of Defence)
19th Apr 2021
To ask the Secretary of State for Housing, Communities and Local Government, what discussions have been had with his ministerial colleagues, if any, to work with the NHS Test and Trace database system.

Government has not provided funding or resources to investigate the potential for MHCLG to make use of the NHS Test and Trace database system.

MHCLG does not use or access identifiable Test and Trace data and has no current plans to do so. Test and Trace data is sensitive health data shared with local authority public health teams on an exceptional basis to support contact tracing and containment of Covid-19, and to provide relevant support to those required to self-isolate. We continue to work with DHSC, the data-owners, to provide guidance to local authorities on how best to use the data


Ministers and officials from my Department have regular discussions with counterparts in other government departments on a range of matters relating to local government.

15th Apr 2021
To ask the Secretary of State for Housing, Communities and Local Government, whether he plans to work with the NHS Test and Trace database system.

Government has not provided funding or resources to investigate the potential for MHCLG to make use of the NHS Test and Trace database system.

MHCLG does not use or access identifiable Test and Trace data and has no current plans to do so. Test and Trace data is sensitive health data shared with local authority public health teams on an exceptional basis to support contact tracing and containment of Covid-19, and to provide relevant support to those required to self-isolate. We continue to work with DHSC, the data-owners, to provide guidance to local authorities on how best to use the data


Ministers and officials from my Department have regular discussions with counterparts in other government departments on a range of matters relating to local government.

15th Apr 2021
To ask the Secretary of State for Housing, Communities and Local Government, whether the Government has provided funding or resources to investigate the potential for his Department to make use of the NHS Test and Trace database system.

Government has not provided funding or resources to investigate the potential for MHCLG to make use of the NHS Test and Trace database system.

MHCLG does not use or access identifiable Test and Trace data and has no current plans to do so. Test and Trace data is sensitive health data shared with local authority public health teams on an exceptional basis to support contact tracing and containment of Covid-19, and to provide relevant support to those required to self-isolate. We continue to work with DHSC, the data-owners, to provide guidance to local authorities on how best to use the data


Ministers and officials from my Department have regular discussions with counterparts in other government departments on a range of matters relating to local government.

19th Apr 2021
To ask the Secretary of State for Justice, whether his Department plans to use the NHS Test and Trace database system.

No assessment has yet been made, nor any decisions made, on whether to use the data systems used by NHS Test and Trace for other purposes beyond those related to Covid-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Chris Philp
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
19th Apr 2021
To ask the Secretary of State for Justice, whether he has allocated any financial or other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace database system.

No assessment has yet been made, nor any decisions made, on whether to use the data systems used by NHS Test and Trace for other purposes beyond those related to Covid-19. Any work to assess potential future uses of these data systems would be met from within the financial resources already allocated to NHS Test and Trace for the 2021/22 financial year.

Chris Philp
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
16th Apr 2021
To ask the Secretary of State for Justice, what discussions he has had with Cabinet colleagues on future uses of the NHS Test and Trace database system.

No such discussions have taken place.

Chris Philp
Parliamentary Under-Secretary (Department for Digital, Culture, Media and Sport)
16th Jun 2021
What assessment he has made of the benefits of the Levelling Up Fund for Northern Ireland.

The Government is firmly committed to levelling up and bringing new benefits and opportunities to communities right across the UK. Through our excellent Levelling Up Fund, £4.8billion is being made available to fund capital projects that will regenerate town centres and high streets, upgrade local transport, and invest in cultural and heritage assets.

In Northern Ireland, the Levelling Up Fund is open to a range of business, voluntary and community sector organisations until 18 June. The successful bids will help drive the recovery of communities and areas hardest hit by Covid. I am confident that this new funding can make a real difference in Northern Ireland and I have enjoyed some enthusiastic early engagements with local government across NI.

Robin Walker
Minister of State (Education)
15th Apr 2021
To ask the Secretary of State for Northern Ireland, what discussions he has had with Cabinet colleagues on using the NHS Test and Trace database system.

The Secretary of State for Northern Ireland and I speak regularly with Cabinet and Ministerial colleagues across Government to discuss a wide range of mutual issues, including the NHS Test and Trace database system. However, the Northern Ireland Office is not the lead UK Government Department responsible for the NHS Test and Trace database system policy. The lead department is the Department for Health and Social Care (DHSC).

As health is a devolved matter, the Department for Health Northern Ireland make their own decisions on testing and tracing, however there is continued UK-wide engagement to ensure a coordinated and collaborative approach.

Robin Walker
Minister of State (Education)
15th Apr 2021
To ask the Secretary of State for Northern Ireland, whether his Department plans to use the NHS Test and Trace database system.

The Northern Ireland Office is not the lead UK Government Department responsible for the NHS Test and Trace database system and does not therefore develop policy relating to the use of the system. The lead department is the Department for Health and Social Care (DHSC).

Robin Walker
Minister of State (Education)
15th Apr 2021
To ask the Secretary of State for Northern Ireland, whether he has allocated any financial or other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace database system.

The Northern Ireland Office is not the lead UK Government Department responsible for the NHS Test and Trace database system, therefore does not allocate resources, including financial resources to investigate future uses of the system. The lead department is the Department for Health and Social Care (DHSC).



Robin Walker
Minister of State (Education)
15th Apr 2021
To ask the Secretary of State for Scotland, what discussions he has had with Cabinet colleagues on using the NHS Test and Trace database system.

I discuss a wide range of issues relating to the Coronavirus pandemic with Cabinet colleagues on a regular basis. However, The Office of the Secretary of State for Scotland is not the lead UK Government Department responsible for the NHS Test and Trace database system policy. The lead department is the Department for Health and Social Care (DHSC).

Public Health is a devolved matter in Scotland. NHS Scotland has created NHS Test and Protect and supports the Scottish Government’s test, trace, isolate and support strategy.

Alister Jack
Secretary of State for Scotland
15th Apr 2021
To ask the Secretary of State for Scotland, whether his Department plans to use the NHS Test and Trace database system.

The Office of the Secretary of State for Scotland is not the lead UK Government Department responsible for the NHS Test and Trace database system and does not therefore develop policy relating to the use of the system. The lead department is the Department for Health and Social Care (DHSC).

Alister Jack
Secretary of State for Scotland
15th Apr 2021
To ask the Secretary of State for Scotland, whether he has allocated any financial or other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace database system.

The Office of the Secretary of State for Scotland is not the lead UK Government Department responsible for the NHS Test and Trace database system, therefore does not allocate resources, including financial resources to investigate future uses of the system. The lead department is the Department for Health and Social Care (DHSC).

Alister Jack
Secretary of State for Scotland
15th Apr 2021
To ask the Secretary of State for Wales, what discussions he has had with Cabinet colleagues on using the NHS Test and Trace database system.

I discuss a wide range of issues relating to the Coronavirus pandemic with Cabinet colleagues on a regular basis. However, The Office of the Secretary of State for Wales is not the lead UK Government Department responsible for the NHS Test and Trace database system policy. The lead department is the Department for Health and Social Care (DHSC).

Simon Hart
Secretary of State for Wales
15th Apr 2021
To ask the Secretary of State for Wales, whether he has allocated any financial or other resources from his Department's budget to investigate potential future uses by his Department of the NHS Test and Trace database system.

The Office of the Secretary of State for Wales is not the lead UK Government Department responsible for the NHS Test and Trace database system and does not therefore develop policy relating to the use of the system. The lead department is the Department for Health and Social Care (DHSC).

Simon Hart
Secretary of State for Wales
15th Apr 2021
To ask the Secretary of State for Wales, whether his Department plans to use the NHS Test and Trace database system.

The Office of the Secretary of State for Wales is not the lead UK Government Department responsible for the NHS Test and Trace database system and does not therefore develop policy relating to the use of the system. The lead department is the Department for Health and Social Care (DHSC).

Simon Hart
Secretary of State for Wales